



①⑫

EUROPEAN PATENT APPLICATION

①⑳ Application number : **92305333.4**

②② Date of filing : **10.06.92**

⑤① Int. Cl.⁵ : **G01N 33/68, G01N 33/53,
G01N 33/569, C12Q 1/68,
C07H 21/04, A61K 48/00,
G01N 33/574**

③① Priority : **14.06.91 US 715182**
31.03.92 US 860758

④③ Date of publication of application :
16.12.92 Bulletin 92/51

⑥④ Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IT LI LU MC NL
PT SE**

⑦① Applicant : **THE JOHNS HOPKINS
UNIVERSITY**
720 Rutland Avenue
Baltimore, MD 21205 (US)

⑦① Applicant : **PHARMAGENICS, INC.**
4 Pearl Court
Allendale, New Jersey 07401 (US)

⑦② Inventor : **Vogelstein, Bert**
3700 Breton Way
Baltimore, Maryland 21208 (US)
Inventor : **Kinzler, Kenneth W.**
1348 Halstead Road
Baltimore, Maryland 21234 (US)
Inventor : **Sherman, Michael I.**
314 Forest Avenue
Glen Ridge, New Jersey 07028 (US)

⑦④ Representative : **Turner, Peter Charles et al**
Withers & Rogers 4 Dyer's Buildings, Holborn
London EC1N 2JT (GB)

⑤④ Sequence specific DNA binding by P53.

⑤⑦ Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.

EP 0 518 650 A2

This work was partially supported by the U.S. government under NIH grants CA06973, CA09243, CA35494, CA09071 and CA43460. The U.S. government retains certain rights in this invention.

TECHNICAL FIELD OF THE INVENTION

This invention relates to diagnostic and therapeutic methods for detecting and alleviating cancers. Specifically it relates to the identification of DNA sequences specifically bound by tumor suppressor p53.

BACKGROUND OF THE INVENTION

The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers (Vogelstein, B., *Nature*, 348:681 (1990)). Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder, and several other organs (S.J. Baker, et al., *Science*, 244:217 (1989); J.M. Nigro, et al., *Nature*, 342:705 (1989); T. Takahashi, et al., *Science*, 246:491 (1989); Romano, et al., *Oncogene*, 4:1483 (1989), Menon, *Proc. Natl Acad. Sci. USA*, 87:5435 (1990); Iggo, et al., *Lancet* ii, 675 (1990); T. Takahashi, et al., *J. Clin. Invest.* 86:363 (1990); Mulligan, *Proc. Natl Acad. Sci. USA*, 87:5863 (1990); Bartek, et al., *Oncogene*, 5:893 (1990); Stratton et al., *Oncogene*, 5:1297 (1990)). One of the important challenges of current cancer research is the elucidation of the biochemical properties of the p53 gene product and the way in which mutations of the p53 gene affect these properties.

Although some biological characteristics of p53 have been defined, such as its ability to suppress the growth of *in vitro* transformed murine cells (Eliyahu, et al., *Proc. Natl Acad. Sci. USA* 86:8763 (1989); Finlay, et al., *Cell*, 57:1083 (1989)) or human cancer cells (Baker, et al., *Science*, 249:912 (1990); Mercer, et al., *Proc. Natl Acad. Sci. USA*, 87:6166 (1990); Diller et al., *Mol. Cell Biol.* 10:5772 (1990)), the biochemical basis of this suppression remains largely unknown. As a step towards understanding such properties, we have attempted to determine whether p53 binds to specific DNA sequences within the human genome.

SUMMARY OF THE INVENTION

It is an object of the invention to provide a method for detecting the presence of wild-type p53 protein in a cell.

It is another object of the invention to provide a method for providing the physiological effect of wild-type p53 protein to a cell.

It is yet another object of the invention to provide a double-stranded DNA fragment which contains a p53-specific DNA binding site.

It is yet another object of the invention to provide a single-stranded oligonucleotide or oligonucleotide containing nucleotide analogs which can specifically complex to a p53-specific DNA binding site.

It is still another object of the invention to provide methods for identifying compounds which specifically bind to p53-specific DNA binding sequences.

It is still another object of the invention to provide methods for identifying compounds which restore the ability of mutant p53 proteins to bind to specific DNA binding sequences.

These and other object of the invention are provided by one or more of the embodiments described below. In one embodiment a method is provided for detecting the presence of wild-type p53 protein in a cell, comprising the steps of: contacting a p53-specific-binding DNA fragment with a cell lysate from a tissue of a human to bind the DNA fragment to wild-type p53 present in the cell lysate; and detecting the binding of the p53-specific-binding DNA fragment to wild-type p53.

In another embodiment of the invention a method is disclosed for providing the physiological effect of wild-type p53 protein to cell, comprising the steps of: providing to a cell a compound which is able to specifically complex with a p53-specific binding site.

In yet another embodiment a double-stranded DNA fragment is provided which comprises a p53-specific-DNA binding site, wherein the fragment comprises more than one monomer repeat of the sequence 5'-RRRCWWGYYY-3' and wherein the fragment is covalently attached to an insoluble polymeric support.

In another embodiment of the invention a single-stranded oligonucleotide containing natural nucleotides and/or nucleotide analogs is provided which is able to complex specifically with a p53-specific binding site, said binding site comprising more than one monomer of the sequence 5'-RRRCWWGYYY-3'.

In yet another embodiment of the invention a method is provided for identifying compounds which specifically bind to p53-specific DNA binding sequences, comprising the steps of: contacting a p53-specific DNA binding fragment immobilized on a solid support with a test compound to bind the test compound to the DNA fragment; and determining the amount of test compound which is bound to the DNA fragment.

In even another embodiment of the invention a method is provided for identifying compounds which specifically bind to p53-specific-DNA binding sequences, comprising the steps of: contacting a p53-binding DNA fragment immobilized on a solid support with both a test compound and wild-type p53 protein to bind the wild-type p53 protein to the DNA fragment; determining the amount of wild-type p53 protein which is bound to the DNA fragment; inhibition of binding of wild-type p53 protein by the test compound suggesting binding of the test compound to the p53-specific DNA binding sequences.

In still another embodiment a method of prescreening agents for use in cancer therapy is provided comprising: measuring the amount of binding of a p53 protein which is encoded by a mutant gene found in cancer cells of a patient to a DNA molecule which comprises more than one monomer of RRRCWWGYYY; measuring the amount of binding of said p53 protein to said DNA molecule in the presence of a test substance; and comparing the amount of binding of the p53 protein in the presence of said test substance to the amount of binding of the p53 protein in the absence of said test substance, a test substance which increases the amount of binding being a candidate for use in cancer therapy.

In another embodiment of the invention a method is provided for prescreening agents for use in cancer therapy comprising: contacting a transfected cell with a test substance, said transfected cell containing a p53 protein which is encoded by a mutant gene found in cancer cells of a patient and a reporter gene construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to the p53 consensus binding site having more than one monomer of RRRCWWGYYY, wherein said sequence is upstream from and adjacent to said reporter gene; and determining whether the amount of expression of said reporter gene is altered by the test substance, a test substance which alters the amount of expression of said reporter gene being a candidate for use in cancer therapy.

In still another embodiment a method of prescreening agents for use in cancer therapy is provided comprising: adding RNA polymerase and ribonucleotides to a transcription construct, said transcription construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to the p53 consensus binding site having more than one monomer of RRRCWWGYYY, said sequence being upstream from and adjacent to said reporter gene, said step of adding being effected in the presence and absence of a test substance; determining whether the amount of transcription of said reporter gene is altered by the presence of said test substance, a test substance which alters the amount of transcription of said reporter gene being a candidate for use in cancer therapy.

In a further embodiment a DNA construct is provided comprising: a reporter gene which encodes an assayable product; and a sequence which conforms to the p53 consensus binding site having more than one monomer of RRRCWWGYYY upstream from and adjacent to said reporter gene; wherein said DNA construct is selected from the group consisting of a recombinant plasmid, a viral vector or an isolated molecule of DNA.

In another embodiment of the invention a method is provided of diagnosing tumor-inducing or hyperplasia-inducing strains of human papilloma virus (HPV) comprising: contacting cells or cell extracts of patients suspected of being infected by HPV with a p53-specific binding DNA fragment; and detecting the amount of wild-type p53 in said cells or cell extract which binds to said DNA fragment, absence of bound p53 indicating infection by strains of HPV which sequester p53.

These and other embodiments of the invention provide the art with new tools for detecting and remedying the loss of function of the most commonly mutated gene identified in human cancers. Further it provides methods for identifying agents which can suppress neoplastic growth.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A. Screening for fragments bound by p53 using an immunoprecipitation assay. Panel 1 contains the hFosAva2 clone; panel 2, 772 C_{BE}; panel 3, Lambda 5R; panel 4, a pool of clones with inserts of randomly cloned human genomic sequences. 772 C_{BE} and Lambda 5R contain HinfI fragments (259 and 190 bp, respectively) which bound p53 relatively strongly (arrowheads). "C" - control lane, containing 2% of the labelled DNA used in the binding reactions. "B" - bound DNA recovered from the immunoprecipitate. Figure 1B. Tests for dependence on p53 and specific antibody. Cell lysates were produced by infection with vaccinia virus that did (+) or did not (-) contain an insert of wild-type p53 cDNA. Immunoprecipitation was performed with anti-p53 monoclonal antibodies (+) or normal mouse IgG (-).

Figure 2. Relative abilities of wild-type and mutant p53 to precipitate fragment A. "C" - control lanes, containing 2% of the labelled DNA used in the binding reaction, "B" - bound DNA recovered from the immunoprecipitate. Figure 2A. Increasing quantities of wild-type and mutant 273^{his} p53, affinity-purified from a baculovirus expression system, were used to precipitate labelled C_{BE} fragments. Figure 2B. Lysates from a vaccinia virus system (Vac) producing the wild-type (wt), mutant (175^{his}), or no p53 protein (-), were used to immunoprecipitate labelled C_{BE} fragments. Equivalent quantities of p53 were present in the wild-type and mutant p53 lysates, as

assessed by Western blot. In the "Bac" lane, affinity-purified p53 produced in baculovirus-infected insect cells was used in place of the vaccinia-infected lysates.

Figure 3A. Fragment A and adjacent vector sequences in the 10d subclone of 772 C_{BE}. This differs from the published 772 C_{BE} sequence (Genbank M25718) in the number of CTT repeats (bp 173-229) and in the presence of A instead of C at bp 116. Figure 3B. Fragment B and adjacent vector sequences in the 8a subclone of Lambda 5R. A related sequence on file (Genbank X05913) varied somewhat from the Lambda 5R subclone studied.

Figure 4. Binding of various subfragments of fragments A and B to p53 from vaccinia-infected cell lysates. Figure 4A. Subfragments of fragment A (subclone 10d) were assayed by immunoprecipitation for their ability to bind wild-type p53 from vaccinia-infected cell lysates. Binding of at least 2% of the DNA added to the reaction was judged as a positive (+) result; lesser but significant binding was recorded as "+/-". Double Lines (=) denote fragment A sequences. Single lines (-) denote polylinker sequences of the vector, not originally present in fragment A (Fig. 1). Fragment 5mut1 had a G to T transversion at bp 120; 5mut2 had G to T transversions at bp 120 to 122. Figure 4B. The fragment A (panels 1-4) and fragment B (panel 5) subfragments illustrated in Figure 4A are labelled to the left of the bands. The "v" band in panel 4 corresponds to the 2.9 kb vector into which subfragment 6 was cloned. Subfragment 8 (panel 5) contained bp 104-238 of fragment B (see Fig. 3B). Control lanes (C) contained 2% of the labelled fragments used in the binding assays (B).

Figure 5. Effects of methylation and point mutations in fragment A on DNA-binding. Figure 5A. Methylation interference assay. "B" - bound DNA recovered from the immunoprecipitate. "C" - equivalent amount of control DNA fragment, not subject to binding reaction. Bound and control DNA samples were cleaved at methylated guanines and equal amount separated by electrophoresis on a 6% denaturing gel. Dots represent methylation-sensitive sites (open for partial, solid for strong interference); some variation in band intensities occurred between assays, and only the reproducible changes are marked. Figure 5B. Binding of "mutant" subfragments of fragment A (5mut1 and 5mut2) to purified baculovirus-produced p53 is compared to that of the normal subfragment 5 sequence. 5mut1 contains a T instead of G at bp 120, and 5mut2 contains Ts in place of Gs at bp 120, 121, and 122.

Figure 6A shows RNase protection analysis of transfected clonal lines. A labeled antisense p53 probe was hybridized with total cellular RNA, and digested with RNase A. Endogenous RNA included all sequences represented in the labeled probe. Exogenous p53 RNA produced from the expression vectors extended only about 2/3 of the length of the probe.

Figure 6B shows Southern blot analysis of transfected clonal lines. The exogenous p53 gene was present on a 1.8 kb BamHI fragment. The endogenous p53 gene gave rise to a 7.8 kb BamHI fragment. Other sized fragments presumably arose by rearrangements.

Figure 7A shows expression analysis of pooled clones; the analysis was as described in Figure 6A.

Figure 7B shows a Southern blot analysis of SW480 pooled clones.

Figure 8. Isolation of human genomic sequences which bound to p53.

Figure 8A. Experimental strategy used for isolation and analysis of human genomic DNA fragments which bound to p53.

Figure 8B. Immunoprecipitation (IP) assays of cloned fragments. Clones of amplified and selected (AS) DNA were tested for the presence of p53-binding fragments by IP. For each clone, the bound DNA is shown in the B lane, adjacent to a control (c) lane containing 2% of the total end-labeled DNA used in the binding assay. In this representative experiment, eight binding fragments were identified, representing six unique genomic fragments. The inserts from the clones in lanes labeled, 2, 3, 5, 9, 10, and 11 contained p53-binding fragment, while the other lanes contained none. The clones in lanes 2 and 5 each contained two binding fragments.

Figure 9. Mapping of p53-binding sites by DNase I protection (DP) and methylation interference (MI). For each footprint, the first and fourth lanes contain control samples of the total labeled DNA, whereas the middle two lanes contain an equivalent amount of p53-bound DNA. DNA sequences corresponding to the p53-binding regions on strand 1 are shown in Fig. 10.

Figure 10. Definition of a consensus binding site for p53. The p53 binding site of 18 cloned human genomic DNA fragments, determined by footprinting methods are displayed along the central axis of symmetry which separates the two 10 bp consensus monomers. Nucleotides in capital letters represent identity of a genomic sequence to the consensus, whereas lower case letters identify disparity with the consensus. Sequences surrounding the consensus or separating the two 10 bp monomers are also shown in lower case. The ten synthetic oligonucleotides investigated for the ability to be bound by p53 are shown at the bottom. Oligonucleotides No. 6 to 10 were tested after cloning into plasmid vectors. Lower case letters represent vector-derived sequences. Combined nucleotide usage (%) within the two monomers of the consensus binding site is shown in the middle.

Figure 11. Binding of synthetic oligonucleotides to wild-type (wt) and mutant p53 proteins.

Figure 11A. The 10 bp consensus monomer was insufficient for binding, whereas dimers in various orien-

tations or multimers of the 10 bp consensus bound strongly to p53. For each sample, the control lane (C) contained 2% of the total DNA used in the binding reaction, and was composed of two fragments: 2.9 kb vector DNA fragment, and a fragment of 40 to 80 bp containing no insert (lane 9; XhoI plus PstI digest of pBluescript II SK+), the 10 bp consensus monomer sequence 5'-AGGCATGTCT-3' (lane 5), or multimers of this sequence arranged as indicated (lanes 1 to 4, 6, to 8). Bound DNA from the IP is shown in the B lanes.

Figure 11B. Comparison of the ability of wild-type and mutant p53 to bind to the consensus dimer. *In vitro* translated p53 proteins were tested for the ability to bind the consensus dimer by IP. Two percent of the total DNA used for binding is shown in lane 1. Lane 7 shows binding to baculovirus-produced human wild-type p53 protein. Lanes 2 to 6 show binding of *in vitro* translated wild-type and mutant p53 proteins. The mutant p53 proteins contained changes at codon 143 (val to ala), 175 (arg to his), 248 (arg to trp), and 273 (arg to his).

Figure 12. Reporter and expression construct used in transfections are shown.

Figure 12A. Reporter constructs in pBluescript II SK+ vector (Stratagene). PG_n, concatemers of n copies of the p53 binding sequence PG. MG_n, concatemers of the mutated sequence, which does not bind p53. CAT, the chloramphenicol acetyltransferase coding sequence. LacZ, the β -galactosidase coding sequence. Py, the early gene promoter from polyomavirus. CYC, the yeast cytochrome c gene promoter.

Figure 12B. Expression vectors. CMV, the cytomegalovirus promoter from the parent vector pCMVneo-Bam. Gal, the galactose-inducible promoter from yeast.

Figure 13. Correlation of DNA-binding and transactivation is shown.

Figure 13A. Relative DNA-binding abilities of various length concatemers of a p53-binding sequence (PG_n series), using an immunoprecipitation assay. Clones were cleaved by restriction endonucleases to extricate the concatemers, end-labelled, incubated with purified baculovirus-produced wild-type human p53, immunoprecipitated with anti-p53 and protein A-Sepharose, and bound fragments recovered and separated on a non-denaturing polyacrylamide gel. C, control lane, containing 2% of the labeled DNA used in the binding reactions. B, bound DNA recovered from the binding reactions.

Figure 13B. Transactivation efficiencies of reporters containing the various PG_n concatemers compared by chloramphenicol acetyltransferase (CAT) assay. 1.7 μ g of the expression vector p53-wt were transfected into HCT 116 cells. Reporters had one orientation of the PG_n sequence (...TGCCT...Py...CAT...), except for PG₂-CAT and PG₁₃-CAT, which had the opposite orientation (...AGGCA...Py...CAT...). Results are expressed relative to the CAT activity in lane 7, which was arbitrarily set at 100.

Figure 14. Comparison of the ability of wild-type and mutant p53 to bind to a concatemerized binding sequence (PG₁₆), and lack of DNA-binding ability to MG₁₅ are shown. Each p53 form (as a rabbit reticulocyte preparation (Promega) made essentially as described in Kern, et al., *Oncogene*, 6:131-136 (1991); equalized for p53 quantity by immunoblot analysis, data not shown) was used to immunoprecipitate end-labeled DNA. C, control lanes, containing 2% of the labeled DNA used in the binding reaction. B, bound DNA recovered from the immunoprecipitate.

Figure 15. Effects of varying the location of the binding sequence relative to the promoter are shown.

Figure 15A. Efficiencies of reporters with PG₁₃ separated by varying distances from the polyomavirus promoter. Various lengths of the non-binding sequence (MG_n series) were used to provide inert spacers of defined length (see Fig. 8A). CAT assays are shown.

Figure 15B. Transactivation efficiency of a reporter with PG₁₆ downstream of CAT (CAT-PG₁₆). 1.7 μ g each of expression and reporter construct were transfected. The MG₁₅-CAT served as a negative control. CAT assays are shown.

Figure 16. Relative abilities of wild-type and mutant p53 to activate transcription are shown.

Figure 16A. Representative CAT assays (Exp. 2 from Table 1).

Figure 16B. Western blot analysis of p53 expression in lysates of transfected cells, showing levels of expression at least as high as that of wild-type p53 were obtained with the mutant p53 clones. In one case (143^{ala}), the level of expression of p53 (lane 3) was slightly lower than with the other constructs, for unknown reasons. When 2.55 μ g of vector was used in the transfection, however, the level produced by the p53-143 vector (lane 7) was at least as high as that for the p53-wt vector, but no transactivation was observed (Table I).

Figure 17. Effect of co-expressed 175^{his} mutant p53 on transactivation by wild-type p53 is shown. 1.7 μ g of PG₁₃-CAT reporter was used with the stated amount of p53 expression constructs. The balance of transfected plasmid was pCMVneoBam (for expressor) and pBluescript II SK+ (for reporter) to a total of 5.1 μ g. CAT assays are shown.

Figure 18. Dominant-negative effect of various mutant p53 proteins are demonstrated. 0.85 μ g of p53-wt was used in all transfections, without or with the addition of 0.85 μ g or 2.55 μ g mutant p53 construct, or with an additional 2.55 μ g p53-wt. 1.7 μ g PG₁₃-CAT reporter was used in each case. The composite results shown are representative of at least two transfections done on separate days.

Figure 19. A biochemical model for the effect of p53 mutations is depicted. Cellular p53 exists as oligomers.

Oligomeric p53 binds its recognition sequence of DNA (shaded thick line) and activates the transcription of adjacent genes (filled box). The depiction of p53 dimers is for illustrative purposes only; tetramers and other forms likely occur. Hetero-oligomerization with mutant proteins inactivates the transactivation function of the participating wild-type p53 molecules, producing the dominant-negative effect of missense p53 mutations. The remaining activity provided by the residual wild-type homo-oligomers is lost upon deletion of the remaining wild-type allele, a frequent event in the progression of human neoplasms.

DETAILED DESCRIPTION OF THE INVENTION

It is a finding of this invention that wild-type p53 protein binds specific fragment of human chromosomal DNA. Each of the fragment contains more than one monomer of the double-stranded motif 5'-RRRCWWGYYY-3' separated by 0 to 13 bp. Some of these sequences are found near origins of replication of certain animal viruses and animal cells. See Jelinek et al, Proc. Natl. Acad. Sci. USA, vol. 77, pp. 1398-1402 (1980). Four mutant forms of p53 protein which are commonly found in human tumors do not have the ability to bind to these sequences. Thus, a function of p53 may be mediated by its ability to bind to specific DNA sequences in the human genome.

Wild-type p53 protein binds specifically to certain DNA sequences. Two previously isolated DNA fragments, called herein fragment A and fragment B, have been identified which contain residues which appear responsible for the binding. These residues are located within DNA segments which contain nucleotides 103-134 of SEQ ID NO:1 and nucleotides 104-198 of SEQ ID NO:2.

Fragment A contains sequences near a putative replication origin of the ribosomal gene cluster, while fragment B contains sequences that may allow adjacent sequences to replicate as extrachromosomal circles in HeLa cells (Sylvester, et al., Gene 84, 193, 1989). The TGCCT repeat present in the DNA binding region of both of these fragments has been observed in other potential replication origins. Thus p53 may be involved in the regulation of initiation of DNA synthesis by virtue of its binding.

It has been found that p53 will specifically bind to other sequences in the human genome with similar sequence motifs. Using a strategy coupling immunoprecipitation to "whole-genome PCR" (Kinzler, et al., Nucleic Acids Research, 17:3645-3653 (1989)), nineteen human DNA fragments that bind to p53 have been identified. Each of the fragments contain a sequence which conforms to a dimer of the double-stranded motif 5'-RRRCWWGYYY-3', separated by 0 to 13 bp. These dimers directly mediate binding, as assessed by DNase I protection and methylation interference assays. The consensus dimers contain a striking symmetry, with four 5'-RRRCW-3' units oriented in alternating directions. A synthetic monomer containing the 10 bp consensus sequence is insufficient for binding, while the combination of two or more monomers bind strongly to wt p53, but negligibly to p53 mutants. Thus, more than one monomer appears to be required for binding. The spacing between monomers may be from 0 to 40 nucleotides, although all natural binding sites isolated have spacings of less than 15 nucleotides. The symmetry of the four half-sites within the consensus dimers suggests that p53 interacts with DNA as a tetrameric protein. The eighteen unique clones shown in Figure 10 allow the identification of adjacent genes which may be regulated by p53 and may mediate its growth-suppressive action.

A sequence which conforms to the consensus sequence need not have the exact sequence of the dimer. As shown in Figure 10, p53-binding sequences can have nucleotides which are different than those designated. There can also be extra nucleotides inserted within the dimer. Nucleotides can also be missing from the dimer. Typically p53-binding sequences will vary from the consensus sequence at no more than 5 nucleotide positions.

It is an additional finding of the present invention that wild-type p53 can activate the expression of genes adjacent to a specific binding site. Moreover, the level of *in vivo* transactivation is proportional to the *in vitro* strength of DNA-binding. Mutant p53 encoded by oncogenic p53 genes (i.e., those found in cancer cells of human patients), completely lose the ability to transactivate. In addition the mutant p53 proteins exert a dominant-negative effect, dramatically reducing the transactivating activity of wild-type p53.

Based on the sequence information of the p53 specific-DNA-binding fragment, a number of diagnostic and therapeutic methods have been devised. According to one such method, cell lysates are tested for the presence or absence of wild-type p53 by virtue of its specific DNA binding ability. As it is known for various cancers and stages of cancers that one or both of the p53 alleles in tumor tissues can be mutant, testing for the presence or absence of wild-type p53 protein can provide diagnostic and prognostic information regarding a tumor and the patient. The cells to be tested are typically isolated from a tissue suspected of being neoplastic. Preferably the tissues are carefully prepared and isolated so that non-neoplastic tissues are not mixed with the neoplastic tissues, which can confound the analysis. Means for separating neoplastic tissues from non-neoplastic tissues are known in the art and include dissection of paraffin or cryostat sections, as well as use of flow cytometry. A cell lysate can be prepared from the tumor tissue according to any method known in the art. The cell lysate is then incubated with DNA fragments which are known to bind the wild-type p53 protein, under conditions which

are conducive to such DNA/protein interactions. Alternatively, a histological sample can be analyzed by incubation with DNA fragments, as described for cell lysates.

It is known that p53 also binds non-specifically to DNA. Specific binding can be distinguished from non-specific binding by any means known in the art. For example, specific binding interactions are stronger than non-specific binding interactions. Thus the incubation mixture can be subjected to any agent or condition which destabilizes protein/DNA interactions such that the specific binding reaction is the predominant one detected. Alternatively, as taught more specifically below, a non-specific competitor, such as dl-dC, can be added to the incubation mixture. If the DNA containing the specific binding sites is labelled and the competitor is unlabeled, then the specific binding reactions will be the ones predominantly detected upon measuring labelled DNA.

According to one embodiment of the invention the DNA which is bound to p53 is separated from unbound DNA by immunoprecipitation with antibodies which are specific for p53. Use of two different monoclonal anti-p53 antibodies may result in more complete immunoprecipitation than either one alone. Unbound DNA remains in suspension. The amount of DNA which is in the immunoprecipitate can be quantitated by any means known in the art. According to one aspect of the invention, the DNA fragment is labelled with a detectable moiety, such as a radioactive moiety, a colorimetric moiety or a fluorescent moiety. Techniques for so labelling DNA are well known in the art. According to other embodiments of the invention, p53 which binds to the specific DNA sequence of the present invention can be detected by gel shift assays (Tan, *Cell*, 62:367, 1990), nuclease protection assays (see Example 9, *infra*), or methylase interference assays (see Example 9, *infra*).

According to another embodiment of the invention, after incubation of p53 with specific binding DNA fragments all components of the cell lysate which do not bind to the DNA fragments are removed. This can be accomplished, among other ways, by employing DNA fragment which are attached to an insoluble polymeric support such as agarose, cellulose and the like. After binding, all non-binding components can be washed away, leaving p53 bound to the DNA/solid support. The p53 can be quantitated by any means known in the art. It can be determined using an immunological assay, such as an ELISA, RIA or Western blotting.

The diagnostic assay of the present invention has applicability not only with regard to cancers which are known to involve mutation of p53, but also with regard to human viruses such as human papilloma virus (HPV). HPV protein E6 binds tightly to wild-type but not mutant p53. See Werness et al., *Science*, 248, 76-69 (1990). This tight binding is likely to block the interaction of p53 with its specific DNA binding sequences. By testing cells or cell extracts suspected of being infected with potentially tumor-inducing or hyperplasia-inducing strains of HPV or possibly other viruses, infected cells can be identified, because the E6 protein of the infected cells will have sequestered the wild-type p53, rendering it unable to bind to its specific DNA binding sequences. Such assays may be performed on cell extracts or on histological specimens.

According to the present invention a method is also provided of supplying wild-type p53 function to a cell which carries mutant p53 alleles. The wild-type p53 gene or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal. In such a situation the gene will be expressed by the cell from the extrachromosomal location. If the mutant p53 genes present in the cell are expressed, then the wild-type p53 gene or gene portion should be expressed to a higher level than that of the mutant gene. This is because the mutant forms of the protein are thought to oligomerize with wild-type forms of the protein. (Eliyahu et al., *Oncogene*, vol. 3, p. 313, 1988.) If a gene portion is introduced and expressed in a cell carrying a mutant p53 allele, the gene portion should encode a part of the p53 protein which is required for non-neoplastic growth of the cell. More preferred is the situation where the wild-type p53 gene or a part of it is introduced into the mutant cell in such a way that it recombines with the endogenous mutant p53 gene present in the cell. Such recombination would require a double recombination event which would result in the correction of the p53 gene mutation. Vectors for introduction of genes both for recombination and for extrachromosomal maintenance are known in the art and any suitable vector may be used.

Polypeptides or other molecules which have p53 activity may be supplied to cells which carry mutant p53 alleles. The active molecules can be introduced into the cell by microinjection or by liposomes, for example. Alternatively, some such active molecules may be taken up by the cells, actively or by diffusion. Supply of such active molecules will effect a less aggressive state of neoplasia.

According to the present invention compounds which have p53 activity are those which specifically complex with a p53-specific DNA binding site. Wild-type p53 is one such compound, but portions of p53 which retain the ability to bind to p53-specific binding sites may also be used. Oligonucleotides and oligonucleotide containing nucleotide analogs are also contemplated among those compounds which are able to complex with a p53-specific DNA binding site. Although applicants do not wish to be bound by any particular theory, it is believed that oligonucleotides bind double-stranded DNA to form triplexes. Such triplexes have been shown to block transcription of certain genes, as well as protect the DNA binding sites from the action of enzymes such as DNA methylases. Although originally such oligonucleotides were thought to require only or predominantly pyrimidines (cytosine and thymine), purines have also successfully been incorporated into triplex forming oli-

gonucleotides. Particular oligonucleotides which may be used include: nucleotides 140-162 of SEQ ID NO:2, nucleotides 128-158 of SEQ ID NO: 1, nucleotides 114-123 of SEQ ID NO: 1, or portions thereof having at least ten nucleotides.

Oligonucleotides containing nucleotide analogs or otherwise modified oligonucleotides may also be useful in the formation of complexes with double-stranded DNA. For example, certain modifications to the 3'-terminus can be employed to reduce the susceptibility of the oligonucleotide to nuclease degradation. Moieties which may be appended to the 3'- or 5'-termini include a substituted or unsubstituted amino group, polyethylene glycol, polylysine, acridine, dodecanol, and cholesterol. Oligonucleotides and oligonucleotides containing nucleotide analogs which may be used include methylphosphonates, aminomethylphosphonates, phosphorothioates, phosphorodithioates, substituted or unsubstituted phosphoramidates, oligoribonucleotides, oligodeoxyribonucleotides, alpha-oligonucleotides and mixtures thereof. Other modifications to oligonucleotides may be desirable to increase the uptake by cells or nuclei of the oligonucleotides or to decrease nuclease sensitivity. All such modifications are within the contemplation of the invention.

Switchback linkers may also be incorporated into the midst of an oligonucleotide or analog. Such linkers are taught by Riordan and Martin (Nature, 350, 452, 1991). They are designed by molecular modeling to provide the proper spacing between portions of an oligonucleotide which are to interact with different strands of a double-stranded DNA molecule. Examples of oligonucleotides having such linkers include the following: TTGCCTTGCT-switchback linker-CCT-switchback linker-CTTGCT (corresponding to nucleotides 105-125 of the double-stranded sequence represented by SEQ ID NO:1) or portions thereof.

Single-stranded, linear or circular oligonucleotides containing nucleotide analogs which are able to complex specifically with all or part of a p53-specific binding site as described above are also contemplated as part of the invention. (See Kool, J. Am. Chem. Soc., vol. 113:625-626, 1991, with regard to circular oligonucleotides.) Such oligonucleotides containing nucleotide analogs should comprise at least about ten nucleotides in length in order to have the requisite specificity with respect to the entire human genome. Oligonucleotides or oligonucleotides containing nucleotide analogs which are able to complex specifically with part of a p53 binding site as well as with adjacent sequences are also contemplated as part of the invention. The oligonucleotides or oligonucleotides containing nucleotide analogs will preferably bind to the identified p53 binding regions. However, other binding regions in the human genome may well be found which are also suitable target for the oligonucleotides or analogs of the present invention. These other binding sites may well be the primary targets of p53; complexation of these sites may inhibit the unregulated growth which characterizes neoplastic cells.

Double-stranded DNA fragments which comprise a p53-specific DNA binding site and are attached to an insoluble polymeric support are also contemplated by this invention. The support may be agarose, cellulose, polycarbonate, polystyrene and the like. Such supported fragments may be used in screens to identify compounds which bind to p53-specific DNA binding sites. Similarly, such supported fragments may be used to perform diagnostic tests on cell lysates from suspected tumor tissues. They may also be used in assays used to screen potential chemotherapeutic agents, as discussed *infra*.

Although any method can be employed which utilizes the p53-specific DNA binding sites of the present invention, two particular methods are disclosed for screening for additional compounds that bind to p53-specific DNA binding sites. According to one method a test compound is incubated with a supported DNA fragment, as described above. The amount of test compound which binds to the supported DNA fragment is determined. This determination can be performed according to any means which is convenient. For example, the amount of a compound which can be removed after incubation with the supported fragment can be compared to the amount originally applied. Alternatively, the test compound can be labelled and the amount which binds to the supported fragment can be assayed directly. In order to render this screening method more specific, soluble DNA fragments which do not contain the p53 DNA binding sequence can be added to the incubation mixture. The soluble fragment would not have the ability to specifically bind to p53 wild-type protein.

According to another screening method for compounds to simulate the specific DNA binding activity of p53, test compounds are incubated with supported DNA fragments as described above. However, in this method wild-type p53 protein is also added to the incubation mixture. The amount of p53 protein which binds to the DNA fragment is measured using methods as described above. The amount of p53 protein bound is compared to the amount which binds in the absence of the test compound. Any diminution of p53 binding which result from the presence of the test compound is presumptively due to the competition of the test compound with p53 for the specific DNA binding sites of the supported fragments. Direct binding of the test compound to the binding site fragments can be confirmed using the assay described above.

The presence or absence of p53 genes or gene products can also be detected in body samples, such as, serum, stool, or other body fluids, such as urine and sputum. The same techniques discussed above for detection of the presence or absence of gene products in tissues can be applied to other body samples. By screening such body samples, a simple early diagnosis can be achieved for many types of cancers. In addition, the

progress of chemotherapy or radiotherapy can be monitored more easily by testing such body samples for the presence or absence p53 genes or gene products.

The methods of the present invention for diagnosis and therapy of neoplastic tissue is applicable across a broad range of tumors. These include lung, breast, brain, colorectal, bladder, mesenchyme, prostate, liver as well as stomach tumors. In addition the method may be used in leukemias and osteosarcomas. It thus appears that the p53 gene has a role in the development of a broad range of tumors. The methods of diagnosis and therapy of the present invention are applicable to any tumor in which p53 has a role in tumorigenesis. The diagnostic method of the present invention is useful for clinicians so that they can decide upon an appropriate course of treatment. For example, a tumor displaying loss of both p53 alleles suggests a more aggressive therapeutic regimen than a tumor displaying loss of only one p53 allele.

Compounds which have p53-specific DNA-binding activity, including wild-type p53 protein, polypeptides corresponding to portions of wild-type p53 protein, oligonucleotides and oligonucleotide containing nucleotide analogues, as well as other organic molecules can also be administered to humans and animals as a pharmaceutical and therapeutic composition. Effective amounts will be administered to cause neoplastic cells to become less aggressively neoplastic or even to stop the growth of the neoplastic cells entirely. Generally, such amounts will be in the range of 10 ng to 10 µg per dose per person or other animal. The therapeutic compounds can be prepared in any conventional pharmaceutical excipient, such as physiological saline or other physiologically compatible aqueous buffer. Typically, the compounds will be administered by injection, either intravenous or intramuscular. However, other administration methods as are known in the art and may be used to administer the compounds of the present invention.

As a result of the discoveries of the present invention, screening methods can be devised to isolate chemical agents which may have use in cancer therapy. Specifically, agents can be screened for the ability to affect the structure of mutant p53 molecules so that their ability to bind and/or transactivate at specific-DNA-binding sites is restored. The necessary components for such a screening method are provided by this invention and include DNA molecules which contain more than one monomer of the sequence RRCWWGYYY, and mutant p53 proteins which are found in tumors.^{1/}

One such prescreening method is a binding assay in which the amount of binding of a p53 mutant protein to a DNA molecule which comprises the consensus binding site (or a conforming sequence) is measured. The amount of binding is also measured for a p53 mutant protein in the presence of a test substance. If the test substance increases the amount of p53 binding, then the test substance is a candidate for use in anti-tumor therapy. Further testing will be desirable before use in humans is attempted.

Methods for measuring the amount of binding can be any which are known in the art. See, e.g., Tan, et al., *Cell*, 62:367-377 (1990). One particular method employs immunoprecipitation. Briefly, purified p53 or a lysate of a cell expressing p53 is incubated with radiolabeled DNA and anti-p53 antibodies under conditions where proteins bind to DNA. Protein A-Sepharose and poly-dIdC-poly-dIdC are then added for an additional incubation. A pellet is formed and washed and the proteins are removed by digestion with a protease, and DNA is obtained by phenol extraction. The extracted DNA is then analyzed by electrophoresis and quantified. Quantitation of the DNA can be by autoradiography, for example. The amount of DNA immunoprecipitated is proportional to the amount of binding of the p53 protein to the DNA.

According to another method, the ability of a mutant p53 protein from a tumor to transactivate transcription *in vitro* is assessed with and without a test substance. If the test substance increases the amount of transcription activated by the p53, then the test substance is a candidate for use in anti-tumor therapy. Transcriptional activation is measured using a transcription construct which comprises a reporter gene encoding a convenient assayable enzyme activity, such as chloramphenicol acetyltransferase or β-galactosidase, and an upstream p53 consensus binding site (or a conforming sequence). The binding site must be upstream, although the distance from the start of transcription is not critical. The binding site, which is adjacent to the reporter gene, may be from 0 to 1 kb upstream. *In vitro* transcription assay systems are well known in the art. See, e.g., Lue, *Science*, 246, 661-664 (1989).

According to still another method, transcriptional activation can be measured in a cell containing a mutant p53 protein which has been transfected with a reporter gene construct comprising a gene encoding an assayable product, such as an enzyme or antigen, with a p53 consensus binding site (or conforming sequence) adjacent and upstream therefrom. The transfected cells are treated with a test substance. If the amount of transactivation caused by the mutant p53 is enhanced by the test substance, then the substance is a candidate for anti-tumor therapy presumably due to its interaction with the mutant protein. A particular transactivation assay

^{1/} Not all mutations in p53 destroy specific-DNA-binding ability. For example, mutations in phosphorylation sites of p53 have been made and tested; they retain binding activity. Such mutations have never been found in tumors. Mutations in p53 which are found in tumors are termed oncogenic herein.

(transient expression assay) is described in Example 12, *infra*. Particular reporter constructs are shown in Figure 12A. Others may be used within the scope of the invention. Alternatively, if the transfected cell contains wild-type p53 diminished activation would indicate that the test substance competes with p53 for binding sites.

In another embodiment of the invention, oligonucleotides can be isolated which restore to mutant p53 proteins the ability to bind to the consensus binding sequence or conforming sequences. Mutant p53 protein and random oligonucleotides are added to a solid support on which p53-specific-binding DNA fragments are immobilized. Oligonucleotides which bind to the solid support are recovered and analyzed. Those whose binding to the solid support is dependent on the presence of the mutant p53 protein are presumptively binding the support by binding to and restoring the conformation of the mutant protein.

Transient expression constructs are conveniently made on plasmids and viral vectors, so that they can be propagated. These can also be used *in vitro* for transcription assays in the presence of RNA polymerase, ribonucleotides, and other cofactors.

EXAMPLES

Example 1

This example demonstrates the screening methods used to identify a p53 sequence-specific binding site.

In an attempt to identify a possible sequence-specific binding site, numerous cloned DNA sequences were screened using an immunoprecipitation technique. The immunoprecipitation assay for DNA-binding was modified from R.D.G. McKay, J. Mol. Biol. **145**, 471 (1981). Binding reactions included 5 μ l of vaccinia-infected cell lysate or purified baculovirus p53 preparations, 95 μ l binding buffer (20 mM Tris pH 7.2, 100 mM NaCl, 10% glycerol, 1% NP-40, 5 mM EDTA), 6-20 $\times 10^4$ dpm 32 P-labelled DNA, 4 μ l (0.4 μ g) pAb421 and 4 μ l (0.4 μ g) pAb1801 anti-p53 purified monoclonal antibodies (Oncogene Science), at 4°C for 30 min. 1.5 mg protein A-Sepharose (Sigma) and 12.5 μ g poly-dIdC-poly-dIdC (Pharmacia), in 25 μ l binding buffer, were added and the reactions rotated end-over-end at 4°C for 30 min. The pellet was washed twice with binding buffer and the proteins digested with SDS-proteinase K, then extracted with phenol and chloroform. The DNA was ethanol-precipitated and dissolved in electrophoresis sample buffer. The fragments were separated on a Tris-borate non-denaturing polyacrylamide (7, 10, or 12%) gel. The gel was fixed and dried for autoradiography.

Recombinant vaccinia viruses expressing p53 from the 40K promoter were isolated and purified as described in J. Lyons et al., *Infect. and Immun.* **58**, 4089 (1990).

Vaccinia-infected cell lysates were prepared as follows: the indicated cells (about 2.5×10^7) were infected (MOI 2), harvested at 24 hrs and lysed in 2 ml lysis buffer (PBS containing 5mM EDTA, 0.5% NP-40, 0.5 mM PMSF, 10 μ g/ml TPCK, 1 μ g/ml aprotinin, 10 μ g/ml trypsin inhibitor, 1 μ g/ml leupeptin). Cell debris was pelleted at 16,000xg and the supernatant UV-irradiated (0.5 joules). The supernatant was frozen in aliquots at -80°C and found to be stable for at least 6 months.

Baculovirus-produced p53 was purified as described in P.N. Friedman, et al., *Proc. Natl. Acad. Sci. USA*, **87**, 9275 (1990); while the presence of an accessory cofactor in the purified preparation cannot be excluded, SDS-polyacrylamide gel electrophoresis of the preparation revealed only a single polypeptide migrating at 53 kD upon silver-staining.

Two classes of clones were tested. The first class consisted of 400 clones containing inserts of 300 to 1000 base-pairs obtained randomly from the human genome. The second class consisted of cosmid and plasmid clones chosen because they contained sequences which might be important in normal growth control. Random human genomic clones were prepared from a partial MboI digest of human DNA; 300-1000 bp fragments were purified and ligated to EcoRI linkers, then cloned into the EcoRI site of pBluescript II (Stratagene). Clones selected because they might be important in normal growth included SP65hFosAva2, containing regulatory sequences from the fos gene, obtained from T Curran; 772 C_{BE} (J.E. Sylvester, R. Petersen, R.D. Schmeckel, *Gene*, **84**, 193 (1989)), from J. Sylvester; a 4.4 kb BglII subclone of Lambda 5R (R. Misra, et al., *Nucl. Acids Res.* **17**:8327 (1989)), from C. Schmid; the c-myc clone was HSR-1 (K. Alitano, et al., *Proc. Natl. Acad. Sci. USA*, **80**, 1707 (1983)) from J. Bishop. Cosmids containing the entire p53 genomic region were from Y. Nakamura; cosmids including the entire DHFR amplicon from hamster cells (B. Anachkova and J.L. Hamlin, *Mol. Cell Biol.* **9**, 532 (1989)) were from J. Hamlin.

Each clone was digested with an appropriate restriction endonuclease, end-labelled with 32 P, and incubated with p53 protein from a lysate of cells infected with a recombinant vaccinia virus expressing p53 protein. Labelled DNA fragments which bound to p53 were then recovered by immunoprecipitation with monoclonal antibodies against p53. Of the more than 1400 restriction fragments tested, only two bound reproducibly to p53 under the experimental conditions used: a 259 basepair HinfI fragment (fragment A) of clone 772 C_{BE} (Panel 2, Fig. 1A), and a 190 basepair HinfI fragment (fragment B) of clone Lambda 5R (Panel 3, Fig. 1A); these frag-

ments bound to a far greater extent than any of the other labelled fragments of larger or smaller size present in the same assay mixes.

Example 2

This example demonstrates that the immunoprecipitation of fragment A is dependent on both p53 protein and anti-p53 antibodies.

The immunoprecipitation assay was performed on fragment A as described in Example 1. Cell lysates were produced by infection with vaccinia virus that did or did not contain an insert of wild-type p53 DNA. Either anti-p53 antibodies were used or normal mouse IgG was used.

Lysates from cells infected with wild-type vaccinia virus (devoid of p53) were not able to specifically immunoprecipitate fragment A (Fig. 1B). Similarly, the detection of the precipitation of fragment A was dependent on the presence of anti-p53 antibodies (Fig. 1B). The binding was evident in lysates prepared from either human HeLa cells or monkey BSC40 cells infected with vaccinia virus and expressing wild-type p53 (Fig. 1B).

Affinity-purified baculovirus-produced wild-type p53 protein was substituted for the vaccinia-infected cell lysates in the immunoprecipitation assay and found to bind fragment A strongly (Fig. 2A). This suggested that the binding to fragment A was an intrinsic property of the p53 polypeptide and not dependent on other factors present in the vaccinia virus-infected cell lysates.

Example 3

The example demonstrates that p53 mutant proteins found in human tumors fail to bind to fragment A.

Increasing quantities of wild-type and mutant 273^{his} p53 protein, affinity purified from a baculovirus expression system, were used to immunoprecipitate labelled fragment from C_{BE}. See Fig. 2A. The proportion of fragment A bound to wild-type p53 protein increased in tandem with the amount of p53 added to the assay mixture (Fig. 2A). In contrast, fragment A did not specifically bind to a mutant form of p53 (273^{his}) protein even at the highest p53 protein concentration used. The 273^{his} mutation is the most common p53 mutant identified in human tumors. Another p53 mutant (175^{his}) protein commonly found in human tumors also failed to bind to fragment A (Fig. 1B).

Example 4

This example defines the particular sequences within fragment A that allow it to bind to wild-type p53 protein.

Fragment A was subcloned, and the 259 bp insert from the subclone (10d, SEQ ID: 1 and Fig. 3A) bound to p53 as expected. A strategy based on the polymerase chain reaction (PCR) and restriction endonuclease digestion was used to generate subfragments of this clone.

One primer for each PCR was labelled with ³²P at the 5' end with T4 polynucleotide kinase in a 5 µl reaction, and the kinase inactivated at 70°C for 5 min. PCR contained 350 ng of each of the appropriate primers and approximately 50 ng plasmid template in a 50 µl reaction, using 25 cycles and the PCR conditions specified in Baker SJ, et al., Cancer. Res., 50:7717 (1990). The products were extracted with phenol and chloroform, ethanol-precipitated, and dissolved in 3mM Tris, 0.2 mM EDTA prior to binding. Subfragment 1 contained bp 1 to 425 of subclone 10d of fragment A (Fig. 3A); subfragments 1a, 1b, 1c, 1d, and 1e were generated by digestion of subfragment 1 with BamHI, MboI, HindIII, HindIII, and BamHI, respectively, from fragment 1. Subfragment 2, contained bp 283 to 425. Subfragment 3a was generated by digestion of subfragment 3 (bp 106 to 294) with Hae III. Subfragment 4a was produced from subfragment 4 (bp 1 to 141) by Hind III digestion. Subfragments 5a and 5b were products of the HaeIII digestion of subfragment 5 (bp 87 to 141). "Mutant" subfragments 5mut1 and 5 mut2 were produced using primers P3ml (5'-GAAAGAAAAGGCAAGGCCAGGAAAGT-3') and P3mut2 (5'-GAAAGAAAAGGCAAGGCCATTAAAGT-3') and were identical to subfragment 5 except for the positions underlined in the primers. Subfragment 6 contained bp 106 to 138, and the insert was excised by restriction with HindIII and BamHI to generate 6a or with HindIII and EcoRI to generate 6b. Subfragment 3, including basepairs 106 to 294 (Fig. 4B, panel 2) bound well to p53 as did subfragment 4, containing basepairs 1 to 141 (Fig. 4B, panel 3). This and similar assays done with additional subfragments (Figs. 4A and 4B) localized the critical sequences to basepairs 106 to 141. This segment contained three repeats of the sequence TGCCT (Fig. 3A). Digestion of subfragment 3 with HaeIII (cleaving between bp 125-126 and removing two of the TGCCT repeats) greatly reduced this binding (Fig. 4B, subfragment 3A, panel 2), suggesting that a critical sequence lay at or near this restriction site and that a single TGCCT repeat was not sufficient for binding. Additional subfragments were tested (#5, bp 87 to 141, Figs. 4A and 5B; #6, bp 106 to 138, Figs. 4A and 4B, panel

4), and it was established that a 33 bp insert containing three TGCCT repeats provided binding capability.

Example 5

5 This example demonstrates that certain G residues are critical for binding of p53 to fragment A.
We studied the requirements for binding at the single nucleotide level using a methylation interference assay. PCR products labelled at one end were generated using primers labelled with T4 polynucleotide kinase (US Biochemicals). The product of each PCR reaction was purified by polyacrylamide gel electrophoresis, eluted from a crushed gel slice in 500 mM ammonium acetate, extracted with phenol and chloroform, and precipitated with ethanol. 2 x 10⁶ dpm of DNA was methylated at guanine residues using dimethylsulfate as described (T. Maniatis, E.F. Fritsch, J. Sambrook, Molecular Cloning; A Laboratory Manual, 1st ed., Cold Spring Harbor Laboratory, 1983, p. 477), ethanol-precipitated and dissolved in 10 µl 3 mM Tris, 0.2 mM EDTA. 0.5 µl was removed as the DNA control. 4.5 µl was added to a binding reaction containing baculovirus-produced p53 or vaccinia-infected cell lysates. The precipitated DNA was purified by SDS/proteinase K digestion, extracted with phenol-chloroform, and ethanol-precipitated. The control DNA and precipitates of bound DNA were cleaved with piperidine at the methylated sites. Equivalent amounts of labelled DNA were loaded and separated on a denaturing polyacrylamide (14.5%) sequencing gel, which was fixed and dried for autoradiography. Subfragment 5, demonstrating efficient binding (Figs. 4A and 5B) was methylated in vitro, and immunoprecipitated after binding to p53. The bound DNA was then cleaved with piperidine at methylated residues and separated by electrophoresis on a sequencing gel. Assay of one strand (Fig. 5A, right) demonstrated that methylation at the G at bp 120 significantly interfered with binding. On the opposite strand (Fig. 5A, left), the most effective interference was produced by methylation at G residues at bp 117, 121, and 122. Partial interference was also produced by methylation at nearby G sites (bp 110-112, 114, and 115). Thus, the methylation interference assay pinpointed one of the central TGCCT repeats (centered at basepair 121) and adjacent basepairs as critical for binding.

To obtain independent evidence of the specificity for the G residues identified by methylation interference, in vitro mutagenesis was used. A DNA fragment was generated that was identical to subfragment 5 except for the substitution of G at bp 120, 121, and 122 with T residues. This "mutant" subfragment (#5mut2) bound poorly to p53 (Fig. 5B). A fragment identical to subfragment 5 except for a single basepair (T substituted for G at bp 120) was then tested. This fragment (#5mut1) also did not bind appreciably (Fig. 5B).

Example 6

35 This example defines the region of fragment B which is important for p53 binding.
Fragment B was subcloned (sequence in Fig. 3B and SEQ ID NO:2). Interestingly, this fragment had two repeats of the TGCCT motif (centered at bp 135 and 152). A PCR strategy similar to that used for fragment A was used to demonstrate that a 95 basepair subfragment (bp 104 to 198), which contained both of these repeats, was sufficient for binding (Fig. 4B, panel 5).

40 Example 7

This example shows that expression of the wild-type p53 gene in human colorectal carcinoma cells dramatically inhibits their growth and that a mutant p53 gene cloned from a human colorectal carcinoma was incapable of exerting such inhibition.

45 The colorectal carcinoma lines SW480 and SW837, which are representative of 75% of colon carcinomas, have each lost one copy of chromosome 17p (including the p53 gene) and the remaining p53 allele is mutated (Baker, et al., Science 244, 217 (1989); Nigro et al, Nature 342, 705 (1989)). The SW837 line contains an arginine to tryptophan mutation at codon 248 (Nigro, supra). The SW480 line contains two point mutations, arginine to histidine at codon 273 and proline to serine at codon 309 (Nigro, supra). The substitutions at codon 248 and 273 are typical of those observed in human tumors, occurring within two of the four mutation "hot spots" (Nigro, supra).

55 For the transfection studies, we constructed a vector, pCMV-Neo-Bam, engineered to contain two independent transcription units. The expression vector pCMV-Neo-Bam was derived from plasmid BCMGNeo-mIL2 (Karasuyama, et al., J. Exp. Med. 169, 13 (1989) by excision of the human beta globin sequences and bovine papilloma virus sequences with Bam HI and Not I. Next, the interleukin 2 (IL-2) sequences present at the unique Xho I site were removed, and the Xho I site was changed to a Bam HI site by linker addition. The vector included CMV promoter/enhancer sequences, which could drive expression of the insert at the Bam HI site, and splicing and polyadenylation sites derived from the rabbit beta globin gene, which ensured proper processing of the

transcribed insert in the cells. A pBR322 origin of replication and β -lactamase gene facilitated growth of the plasmid in *E. coli*. The plasmid conferred geneticin resistance through expression of the neomycin resistance gene under separate control of an HSV thymidine kinase promoter. The first transcription unit comprised a cytomegalovirus (CMV) promoter/enhancer upstream of a site for insertion of the cDNA sequences to be expressed, and splice and polyadenylation sites to ensure appropriate processing. The second transcription unit included a herpes simplex virus (HSV) thymidine kinase promoter/enhancer upstream of the neomycin resistance gene, allowing for selection of transfected cells in geneticin.

A wild-type p53 cDNA was inserted into pCMV-Neo-Bam to produce pC53-SN3. Similarly, a vector, pC53-SCX3, expressing a mutant cDNA from human colorectal tumor CX3, was also constructed. The only difference between pC53-SN3 and pC53-SCX3 was a single nucleotide (C to T) resulting in a substitution of alanine for valine at p53 codon 143 in pC53-SCX3. The two constructs were made as follows: a 1.8-kb Xba I fragment, extending from nucleotide -130 to 1671 relative to the translation initiation site, was isolated from wild-type or CX3 cDNA clones. The fragment was blunt-ended with the Klenow fragment of DNA polymerase, ligated to Bam HI linkers, and cloned into the unique Bam HI site in the expression vector pCMV-Neo-Bam.

The constructs were transfected into SW837 and SW480 cells (obtained from the American Type Culture Collection, Rockville, Maryland), and geneticin-resistant colonies were counted 3 weeks later. Cells transfected with pC53-SN3 formed five-to tenfold fewer colonies than those transfected with pC53-SCX3 in both recipient cell types (Table 1).

Table 1. Colony formation after transfection with wild-type and mutant p53 expression vectors. For each experiment, one or two 75-cm² flasks were transfected, and the total colonies counted after 3 to 4 weeks of selection in geneticin (0.8 mg/ml). Exp. experiment.

| Cell line | Exp. | No. of geneticin-resistant colonies formed | |
|-----------|------|--|----------------------|
| | | pC53-SCX3 (mutant) | pC53-SN3 (wild-type) |
| SW837 | 1 | 754 | 66 |
| | 2 | 817 | 62 |
| SW480 | 1 | 449 | 79 |
| | 2 | 364 | 26 |
| RKO | 1 | 1858 | 190 |
| | 2 | 1825 | 166 |
| VACO 235 | 1 | 18 | 16 |
| | 2 | 26 | 28 |

In both SW837 and SW480 cells, the number of colonies produced by the expression vector pCMV-Neo-Bam (without a p53 cDNA insert) was similar to that induced by the pC53-SCX3 construct.

These results suggest that the wild-type p53 gene inhibits the clonal growth of both the SW837 and SW480 cell lines; however, a significant number of colonies formed after transfection of the wild-type construct. If wild-type p53 expression were truly inhibitory to cell growth, one would expect that no colonies would form or that p53 expression in the colonies that did form would be reduced compared to that produced with the mutant p53 cDNA construct. To evaluate this issue, we expanded independent SW480 and SW837 colonies into lines, and ribonuclease (RNase) protection analysis was performed to determine the amount of p53 mRNA expressed from the exogenously introduced sequences. Twelve of 31 lines (38%) derived from transfection with the pC53-SCX3 construct were found to express the exogenous mutant p53 mRNA. This percentage was consistent with results expected in human cells transfected with a vector containing two independent transcription unit. Previous studies have shown that, in contrast to rodent cells, primate cells are able to integrate only a small amount of foreign DNA (approximately 6 kb), so that only 10 to 30% of clones selected for the expression of one tran-

scription unit also contain the second unit in an intact form (F. Collabere-Garapin, et al., *Gene* 50, 279 (1986); Hoeijmakers, et al., *Exp. Cell Res.*, 169, 111 (1987); Mayne et al., *Gene* 66, 65 (1988), Dean, et al., *Exp. Cell Res.*, 183, 473 (1989). In contrast, no expression of exogenous p53 wild-type mRNA was seen in any of 21 clonal lines established from either SW480 or SW837 cells transfected with the pC53-SN3 vector (Fig. 6A). These RNase protection results were supported by analysis of the exogenous p53 DNA sequences within the clones. All of the p53-expressing clones derived from the pC53-SCX3 transfection contained an intact copy of the exogenous p53 gene (Fig. 6B). In contrast, in all the clones derived from the pC53-SN3 transfection, the exogenous p53 sequences were deleted or rearranged (Fig. 6B).

The results from individual clones were further supported by the analysis of pooled clones, in which numerous colonies could be simultaneously assessed. Forty or more clones from two to three separate transfection experiments were pooled and analyzed approximately 3 weeks after transfection. RNase protection studies showed substantial expression of wild-type sequences was not detectable (Fig. 7A). Result from Southern (DNA) blotting were consistent with the RNase protection studies, in that pooled colonies from the wild-type transfectants had no detectable unrearranged exogenous p53 sequences, in contrast to the intact p53 sequences in colonies derived from the mutant p53 cDNA expression vector (Fig. 7B).

The conclusions made from the above experiments are dependent on the assumption that p53 protein was produced in the transfected cell lines. Clones containing exogenous mutant p53 sequences produced p53 mRNA at a concentration 1.5 to 3.5 times higher than that produced by the endogenous p53 gene (Figs. 6A and 7A). Immunoblot analysis showed that there was a concomitant small increase in p53 protein expression in the transfectants (1.5- to 3-fold) compared to the untransfected cells. However, this increase was difficult to measure quantitatively, since these cells produced significant amounts of endogenous p53 protein that (unlike endogenous p53 mRNA) could not be distinguished from that produced by the vectors. To confirm that transfected human cells expressed p53 protein from our constructs, we studied an additional colorectal carcinoma cell line (RKO). RKO cells were obtained through the generosity of M. Brattain. Although RKO cells did not contain a mutation within the susceptible p53 coding sequences, i.e., exons 5-9, they expressed low concentrations of p53 mRNA compared to normal colorectal mucosa or the other lines studied and did not produce detectable amount of protein.

Results of colony formation assays in transfected RKO cells were similar to those in SW480 and SW837 cells. Colony formation by wild-type p53 gene transfectants occurred with a tenfold decrease in efficiency compared to the mutant p53 construct (Table 1). Immunocytochemical detection of p53 protein in transfected RKO cells was done as follows: approximately 5×10^4 cells were cytocentrifuged onto polylysine-coated slides, fixed for 10 min in formalin, and permeabilized for 5 min in 0.5% Triton X-100. A mouse monoclonal antibody against human p53 protein (Ab1801) in combination with the ABC immunoperoxidase system (Vector Laboratories), was used for immunocytochemical detection of p53 protein (Banks, et al., *Eur. J. Biochem.* 159, 529 (1986)). Ten to 20 randomly selected microscopic fields were analyzed per slide. These observations are consistent with the greater stability of mutant compared to wild-type p53 protein noted previously (C.A. Finlay et al., *Mol. Cell Biol.* 8, 531 (1988)). However, transient mRNA expression was also significantly lower in the SN3 transfectants compared to the SCX3 transfectants at 48 and 96 hours, supporting the idea that RKO cells expressing wild-type p53 were at a selective disadvantage compared to those producing mutant p53 products.

To obtain additional evidence that cells expressing p53 were inhibited in their growth potential, we examined the effect of p53 gene expression on DNA synthesis in transfected RKO cells were labeled with [3 H] thymidine for 2 hours. The cells were subsequently fixed, immunocytochemically stained for the presence of p53 protein, and autoradiographed. The number of cells undergoing DNA replication was only slightly lower in cells producing exogenous mutant p53 protein than in cells that did not express any detectable p53 protein. Expression of the wild-type protein, however, dramatically inhibited the incorporation of thymidine (Table 2).

Table 2. Immunocytochemistry and [³H]thymidine incorporation of transfected RKO cells.

| Plasmid | Percent of cells expressing p53 protein at | | | | Percent of cells incorporating [³ H]thymidine in | |
|-----------|--|--------|--------|--------|--|--------------------|
| | 6 hrs | 24 hrs | 48 hrs | 96 hrs | p53 expressors | p53 non-expressors |
| pC53-SCX3 | 1.0 | 11 | 4.3 | 2.0 | 24 | 31 |
| pC53-SN3 | 1.9 | 5.2 | 0.3 | 0.2 | 1.7 | 33 |

These results all suggested that wild-type p53 exerted an inhibitory effect on the growth of carcinoma cells *in vitro*. To evaluate whether this inhibitory effect was cell type-specific, we transfected colorectal epithelial cells derived from a benign tumor of the colon (the VACO 235 adenoma cell line). VACO 235 cells are described by J.K.V. Willson et al., Cancer Res., 47, 2704 (1987). Previous studies have shown that most adenomas contain two copies of chromosome 17p and express wild-type p53 mRNA at concentrations similar to that of normal colonic mucosa. Analogously, the p53 alleles of the VACO 235 cell line were sequenced (exons 5-9) and found to be wild-type and the expression of p53 mRNA was found to be similar to that of normal colorectal mucosa. In contrast to the results seen with SW480, SW837, and RKO cells, the pC53-SN3 and pC53-SCX3 constructs produced similar numbers of geneticin-resistant colonies after transfection of the VACO 235 line (Table 1). We considered, however, that the most definitive test for differential growth inhibition by wild-type versus mutant p53 genes involved analysis of exogenous p53 expression in pooled transfectants. Through such analysis, a large number of colonies could be examined simultaneously and the expression of exogenous mutant and wild-type p53 genes directly compared. Striking differences in the relative expression from the transfected genes were seen in all three carcinoma cell lines tested. VACO 235 transfectants, however, expressed similar amounts of exogenous p53 mRNA from either pC53-SN3 (wild-type) or pC53-SCX3 (mutant) p53 construct (Fig. 7A).

In summary, our results suggest that expression of the wild-type p53 gene in colorectal carcinoma cell lines was incompatible with proliferation. The inhibitory effects of wild-type p53 were specific in two ways. First, a single point mutation in a p53 gene construct abrogated its suppressive properties as measured by three separate assays (colony formation, exogenous p53 expression in transfected clones, and thymidine incorporation). The CX3 mutant provided a control for gene specificity as it contained only one conservative mutation, resulting in a substitution of one hydrophobic amino acid (alanine) for another (valine) at a single codon. Second, the growth-suppressive effect of the wild-type p53 construct was cell type-specific. Introduction of the wild-type vector into the VACO 235 adenoma cell line had no measurable inhibitory effect compared to the mutant p53 vector. There are several differences between the cell lines that could account for the differential effect of the introduced vectors. Regardless of the basis for the difference, the results with the VACO 235 cell line minimize the possibility that the wild-type p53 construct had some nonspecific, toxic effect on recipient cells; the effect was cell type-dependent.

The transfection and expression results of Table 1 and Fig. 7A suggest that cells at the premalignant stages of tumor progression (VACO 235) may be less sensitive to the inhibitory effect of wild-type p53 than malignant cells (SW480, SW837, and RKO). This hypothesis is consistent with previous results that suggest the wild-type p53 is less inhibitory to the growth of normal rat embryo fibroblasts than to their oncogene-transfected derivatives. Finlay et al., Cell 57, 1083 (1989); Eliyahu et al., Proc. Natl. Acad. Sci. USA, 86, 8763 (1989). This sensitivity may only be relative: expression of the wild-type gene at high concentrations might inhibit the growth of any cell type, including non-neoplastic cells, by overwhelming normal regulatory processes such as phosphorylation. Samad et al., Proc. Natl. Acad. Sci. USA, 83, 897 (1986); Meek et al., Mol. Cell Biol. 8, 461 (1988). Genetic alterations that occur during the progression of colorectal tumors may increase the sensitivity of cells to p53 inhibition, making wild-type p53 expression a key, rate-limiting factor for further tumor growth and expansion. At this point, and not before, mutations in the p53 gene would confer a selective growth advantage to cells *in vivo*, which would explain the frequent occurrence of p53 gene mutations and allelic loss only in the more advanced stages of colorectal tumorigenesis.

Example 8

This example demonstrates the identification of human genomic fragments that can bond to wt p53 protein *in vitro*.

5 This schema in Figure 8A outlines the experimental strategy used for the isolation and analysis of p53 binding sites. Total human genomic DNA fragments were ligated to specially designed "catch" linkers (Kinzler, et al. (1989), *Nucleic Acids Research*, 17:3645-3653, and Kinzler, et al. (1990), *Molec. Cell. Biol.*, 10:634-642) to allow for subsequent PCR amplification and cloning. The linked genomic DNA was then incubated with wt p53 and precipitated with anti-p53 antibodies. The bound DNA was subsequently amplified by PCR using primers
10 complementary to the catch linkers, and the process repeated. After four rounds of sequential immunoprecipitation and PCR, the amplified and selected (AS) DNA was cloned. Clones were picked at random and tested for p53 binding first by immunoprecipitation (IP), and then by methylation interference (MI) and DNase I protection (DP).

15 Following the outline in Figure 8A., we tested the inserts of 530 clones for binding to p53. Restriction fragment of the clones were end-labeled and incubated with purified human wt p53 protein produced in baculovirus-infected cells.

Whole-genome PCR was performed as previously described, except that only one oligonucleotide (5'-GAGTAGAATTCTAATATCTC-3') was used for amplification (Kinzler, et al. (1989), *Nucleic Acids Research*, 17:3645-3653, and Kinzler, et al. (1990), *Molec. Cell. Biol.*, 10:634-642). Two hundred ng of "catch"-linked human genomic DNA were incubated with 100 ng of baculovirus-produced human wt p53 purified as described
20 (Friedman, et al. (1990), *Proc. Natl. Acad. Sci. U.S.A.*, 87:9275-9279), and immunoprecipitated as described below. After 4 rounds of IP and PCR, the AS DNA was cleaved with Eco RI and cloned into either the vector Lambda Zap II or pBluescript II SK+ (Stratagene). Individual clones were picked at random and tested for p53 binding. In panel B, cloned plasmid DNA samples were cleaved with Eco RI and end-labeled by Klenow fill-in.
25 For IP (McKay, et al. (1981), *J. Mol. Biol.*, 145:471-479), ten ng of DNA were incubated with 100 ng of baculovirus-produced human wt p53 and 100 ng of poly dI-dC at 4°C for 30 minutes in 100 µl of "DNA-binding buffer" containing 100 mM NaCl, 20 mM Tris, pH 7.0, 10% glycerol, 1 % NP40, and 5 mM DTT. DNA fragments bound to p53 were complexed to antibodies by the addition of 8 µl containing 400 ng each of anti-p53 antibodies pAb421 and pAb1801, both obtained from Oncogene Science, and incubated for 30 minutes at 4°C. The DNA-
30 binding buffer containing 1.5 mg protein A precipitated following the addition of 26 µl of DNA-binding buffer containing 1.5 mg protein A Sepharose and 10 µg of poly dI-dC and mixing at 4°C for 30 minutes. After removal of the supernatant, the immunoprecipitate was washed twice with 1 ml of DNA-binding buffer. Bound DNA was purified by treatment with SDS and proteinase K at 48°C for 30 minutes, extracted with phenol and chloroform, precipitated with ethanol, separated by electrophoresis on a 10% nondenaturing polyacrylamide gel, and au-
35 toradiographed.

Twenty-three of the clones were found to contain fragments that bound to p53. Examples of the IP experiment are shown in Figure 8B. Clone S61 (lanes 11B,C) contains a single genomic fragment of 202 bp which bound to p53. Clone N2 contained five fragments, only one of which (357bp) bound to p53 (lanes 10B,C). Other
40 examples of p53-binding fragments were obtained, and each of these was subcloned for further analysis. In contrast, we found that none of over 1000 clones containing unselected human DNA inserts of similar size bound to p53 using the IP assay. Thus, the whole-genome PCR procedure significantly enriched for p53-binding sequences.

Example 9

45 This example demonstrates the localization of p53 contacts with bound DNA fragments.

Localization of the regions bound by p53 was obtained by DP or MI assays using the subcloned DNA fragments as probes. For MI, the fragments were methylated at G residues and bound to p53 (Fig. 9). Methylation of G residues critical for p53 binding resulted in interference with IP. For example, methylation at nucleotides,
50 217, 22, 227 to 229, and 233 of the 248 bp insert from clone 11B3 completely interfered with the binding of this fragment to p53 (Fig. 9, footprint 2). When the opposite strand was analyzed, interference was observed at the G residues corresponding to nucleotides 219, 223, 224, 230, 235, and 236 (Fig. 9, footprint 1). For DP, labelled DNA fragments were first subject to IP, then incubated with various amounts of DNase I. For clone
55 N22, p53 binding provided protection against DNase I cleavage at residues 187 to 211 (Fig. 9, footprint 9). MI showed interference by G residues only within the region protected by DNase I (Fig. 9, footprint 10). Other examples of DP and MI mapping are shown in Figure 9. p53-binding DNA fragments were subcloned and labeled on one end, gel-purified and subjected to DP or MI mapping. For MI, 10 ng of DNA were incubated in 200 µl of 50 mM Na-cacodylate, 1 mM EDTA, pH 8.0 and 5 µl of 10% dimethylsulfate/90% ethanol for 5 minutes at

20°C to methylate G residues. Fifty μ l containing 1.5 M Na-acetate, 1 M β -mercaptoethanol and 60 μ g of glycogen were added. The mixture was ethanol-precipitated, washed, and resuspended in 5 μ l of 3mM Tris, 0.2 mM EDTA, pH 7.5, and allowed to bind to wild-type p53 as described in the legend to Figure 1. After IP and DNA purification, the samples were incubated with 100 μ l of 1 M piperidine at 90°C for 30 minutes. The samples were then dried under vacuum and separated electrophoretically on a 6% polyacrylamide sequencing gel. The control DNA samples were carried through all incubations except no p53 was added. For these control samples, the protein A Sepharose pellets were treated with SDS and proteinase K without removal of the supernatants (which contained the labeled DNA in the absence of p53).

For DP assays, end-labeled DNA fragments were immunoprecipitated as described in the legend to Figure 8. The protein A Sepharose pellet were incubated for two minutes at 25°C with 200 ng DNase I in 5 mM MgCl₂. After purification of the DNA, as described above, samples were separated by electrophoresis on sequencing gels and loaded as described above for MI. MI was performed on all 18 genomic DNA fragments which bound to p53. DP assays were performed on 13 fragments and the regions of protection uniformly coincided with those indicated by the MI assays.

Example 10

This example analyzes the sequences of p53-bound DNA regions.

We next compared the sequences of the twenty-three clones. The average insert sequence was 307 bp (range 139-470). We found that ten of the twenty-three clones were not unique, showing at least one hundred contiguous nucleotides identical to one other clone. Thus, the twenty-three clones represented only eighteen independent genomic DNA fragment. We attempted to find similarities among these eighteen fragments by computer methods, but found no significant relationships. However, when we aligned the regions involved in p53 binding (as assessed by MI and DP), a striking and consistent feature of the clones became apparent (Fig. 10). Each of the binding sites contained two copies of the 10 bp motif 5'-RRRCWWGYYY-3', separated by 0 to 13 bp. One clone (S592) contained two separate areas of footprinting, and both regions contained a dimer of the 10 bp motif (Fig. 10). In all clones, the regions displaying DP and MI were always centered within the dimers, and G residues within the 10 bp motif strongly interfered with binding to p53 (examples in Fig. 9). The 10 bp consensus monomer contained an internal symmetry, with two oppositely oriented half-sites of the form 5'-RRRCW-3'. This symmetry was extended in the dimers, which contained four half-sites oriented in alternating directions, forming a pseudopalindromic structure, sometimes with an intervening loop. This consensus dimer was also recognized in the p53 binding sequence mapped within plasmid CBE10d (Fig. 10). Despite the remarkable symmetry noted for all p53 binding sequences, none of the genomic sites were palindromic.

Example 11

This example demonstrates that a dimer of the consensus motif is required to bind p53 and that mutant p53 proteins found in tumors do not bind to the consensus sequence.

To determine if the 10 bp consensus monomer could bind to p53, a synthetic oligonucleotide (5'-AGG-CATGTCT-3') containing the consensus sequence was studied. Oligonucleotide duplexes were tested either directly or after cloning into plasmid vectors. The monomer was found not to bind to p53, either alone (not shown) or flanked by 43 nucleotides of plasmid sequences (Fig. 11A, lane 5). In contrast, the dimers (composed of two copies of the monomer arranged in head-to-head, tail-to-tail, or head-to-tail orientation), each bound strongly to p53 protein (Fig. 11A, lanes 1 to 4, 6). Higher-order oligomers of the monomer did not bind any better than the dimer in the IP assay (Fig. 11A, lanes 6 to 8). A different monomer, still fitting the consensus sequence, but perfectly palindromic, also bound as a dimer but not as a monomer (Fig. 10, synthetic oligonucleotides 3,4). Two variants of the consensus motif were also tested for binding. In the first, the two critical G:C bp's at position 4 and 6 of the monomer were substituted with A:T bp's (Fig. 10, synthetic oligonucleotides 1,2). Although this sequence was perfectly symmetrical, it did not bind to p53 either as a monomer or as a dimer. We also tested direct repeats of the 5'-PuPuPuC(AT)-3' half-site, and found that these did not bind to p53 (Fig. 10, synthetic oligonucleotide 5). Thus, the mirror-image symmetry of the half-sites within the 10 bp consensus monomer was critical for its activity.

Finally, we tested p53 mutants representing each of the four "hot-spots" frequently altered in human cancers ((Nigro, et al. (1989), *Nature*, 342:705-708, and Holstein, et al. (1991), *Science*, 253:49-53) for ability to bind to the consensus dimer. None of the p53 mutants bound appreciably to this sequence (Fig. 11B) under conditions where the wt protein bound strongly. These experiments also showed that *in vitro* translated p53, as well as that purified from baculovirus-infected insect cells, had the capacity to bind DNA specifically.

In summary, a set of human genomic DNA sequences which could bind p53 were isolated and used to de-

fine a consensus binding sequence for p53. The symmetry of the four half-sites within the consensus dimers suggests that p53 interacts with DNA as a tetrameric protein. This is consistent with studies suggesting that p53 assembles into homotetramers (Krais, et al. (1988), *J. Virol.*, 62:4737-4744, and Weinberg (1991), *Science*, 254: 1138-1146).

Example 12

This example demonstrates that intact p53 can activate expression in human cells.

We first made reporter plasmids (PG_n-CAT series) containing part of the polyomavirus early promoter and the CAT gene located downstream of DNA sequences which could bind to p53 *in vitro* (Figure 8). For the CAT reporters, concatemers of the p53-binding region of C_{BE} were formed by ligation of complementary oligonucleotides, ligated into the EcoRV site of pBluescript II SK+ (Stratagene) to form the PG_n and MG_n series. The BglII-BamHI fragment of pPyOICAT (Murakami, et al. (1990) *Oncogene*, 5:5), containing the polyomavirus early promoter and the CAT gene coding region, was ligated into the BamHI site of the PG_n and MG_n series clones to form the PG_n-CAT and MG_n-CAT series, and the orientation of the inserts characterized by restriction enzyme analysis. The PG₉-MG_n-CAT and PG₁₃-MG_n-CAT series were formed by excising the HindIII-Sall fragments of PG₉-CAT and PG₁₃-CAT, blunt-ending, attaching XbaI linkers, and ligating into the XbaI site of the MG_n-CAT series plasmids (where n=1, 5, 10, and 15). For the yeast β -galactosidase reporter plasmids, PG and MG sequences were ligated as Sall-SmaI fragments to the Sall and filled-in XhoI sites of pCZ (Buchanan, et al. (1988), *Mol. Cell Biol.*, 8:50806). The construction of the p53-wt expression construct has been described (Baker, et al. (1990), *Science*, 249:912); the mutant expression plasmids were constructed similarly from the previously described cDNA plasmids (Nigro, et al. (1989), *Nature*, 342:705, and Kern, et al. (1991), *Oncogene*, 6:131), or in the case of the engineered phosphorylation site mutants, by *in vitro* mutagenesis (Altered Sites, Promega) with verification by sequencing. The construction of the yeast p53 expression vectors based on pRS314 has been described (Nigro, et al., *Mol. Cell Biol.* (in press)).

For the p53 binding sequences, we used a series of concatemers of the oligonucleotide PG (5'-CCTGCCTGGACTTGCCTGG-3'). This contained the binding region of plasmid C_{BE}, previously shown to bind p53 *in vitro*. The reporter and an expression vector coding for the intact human wild-type protein (p53-wt) (Fig. 12B), were transfected together into the human colorectal cancer cell line HCT 116. This line makes low amount of apparently wild-type p53 protein.

Exons 5-8 of the p53 genes from HCT 116 cells were amplified by PCR and sequenced as described in Sidransky et al. (1991), *Science*, 252:706. Previously, these exons had been shown to contain over 90% of the mutations observed in human tumors. No mutations were observed from HCT 116 cells. Small amount of apparently wild-type protein could be detected in Western blots of HCT 116 protein (See Fig. 16B).

The intact wild-type p53 protein was indeed able to activate transcription (Fig. 13). We found that the level of transactivation of the CAT gene depended on the strength of binding to p53 of the upstream sequences. Thus, the longer the number of PG repeats, the greater the binding to p53 *in vitro* (Fig. 13A) and the higher the CAT expression *in vivo* (Fig. 13B, lanes 1-7). The level of transactivation also increased with the amount of p53 expression vector transfected (Table 3).

Table 3. Transactivation in human cells

| p53 Expression Vector ^{2/} | Reporter | Exp. 1 | Relative CAT Activity ^{1/} | | |
|---|------------------------------------|--------|-------------------------------------|--------|--------|
| | | | Exp. 2 .85 µg | 2.55µg | Exp. 3 |
| p53-wt | PG ₁₃ CAT | 100 | 100 | 210 | 100 |
| Tumor-derived mutations: | | | | | |
| p53-143 | PG ₁₃ CAT | 3 | 1 | 4 | |
| p53-175 | PG ₁₃ CAT | 2 | 3 | 6 | |
| p53-248 | PG ₁₃ CAT | 2 | 4 | 7 | |
| p53-273 | PG ₁₃ CAT | 2 | 2 | 3 | |
| Endogenous activities: | | | | | |
| p53-wt | MG ₁₅ CAT ^{3/} | | <1 | | 2 |
| none ^{4/} | PG ₁₃ CAT | | 20 | | 2 |

1/ All transfections used 1.7 µg reporter in HCT 116 cells. Transfection and CAT assays were performed as described (Sadransky, et al. (1991), *Science*, 252:706). Activities reflect the fraction of chloramphenicol converted to an acetylated form, expressed as relative values with one transfection of each experiment arbitrarily designated as having a value of 100. Three representative experiments (Exp.) shown.

2/ Experiment 2 used both 0.85 and 2.55 µg levels of expressor. Experiment 1 used 1.7 µg, and experiment 3 used 0.85 µg.

3/ MG₁₅-CAT provided a control for DNA-binding specificity and an estimate of background from promoter-independent "readthrough" transcription and/or basal promoter activity.

4/ The expressor-negative transfection provided an estimate of the activity from endogenous wild-type p53 of the HCT 116 cells. In various transfections, the endogenous activity was 2-20% of that following transfection with exogenous wild-type p53, depending on the efficiency of transfection. The activity from endogenous p53 was diminished by transfection of oncogenic mutant p53.

Specificity for the binding sequences was tested by replacing six GC basepairs in the 18-basepair oligonucleotide to generate a mutant form of PG, termed MG (5'-CCTTAATGGACTTTAATGG-3'). This sequence, when

multimerized and placed upstream of the CAT reporter, did not bind to p53 *in vitro* (Fig. 14, lanes 7 and 8), nor did it activate CAT expression *in vivo* (Table 3; Fig. 13B, lane 8; Fig. 15A, lane 6, Fig. 15B, lane 2). The trans-activation of CAT was independent of the orientation of the PG multimer upstream of the CAT gene (Fig. 13B). Placing an additional 59 to 333 basepairs between the PG multimer and the promoter also had little effect on transactivation (Fig. 15A, lanes 2-5). However, placement of the PG binding sequences downstream of the CAT gene did not allow transactivation (Fig. 15, lane 3). These observations indicated that the PG sequences act as an upstream activator element, although not as a classical enhancer.

CAT assay. Cultures of HCT 116 cells at 50-80% confluence in 25 cm² flasks were transfected using Lipofectin (BRL, Gaithersburg, MD) according to the manufacturer's instructions. All flasks within an experiment were transfected with the same total amount of plasmid using pCMVneoBam or pBluescript II SK+ as "filler". Cells were harvested at 20-24 hr. and the CAT activity of the lysates measured by acetylation of ¹⁴C-labeled chloramphenicol (ICN) as previously described (Gorman, et al. (1982), *Mol. Cell Biol.*, 2:1044). The Bio-Rad protein assay was used to assure equivalence of lysate protein. Percent conversion to the acetylated form of chloramphenicol was calculated after quantitation by scintillation counting of excised chromatographic spot. Results reported are representative of at least two transfections done on separate days.

Example 13

This example demonstrates that oncogenic mutant p53 genes consistently fail to transactivate.

The precise correlation between the binding of the PG multimer *in vitro* (Fig. 13A) and the expression from PG_n-CAT reporters *in vivo* (Fig. 13B) strongly suggested that this expression was a direct result of p53 binding to PG multimers *in vivo*. If such an activity of p53 were crucial to its tumor suppressor activity, one would expect that naturally occurring mutants of p53 would be defective in this function. p53 mutations generally occur in four different p53 "hot-spot" regions, representing four evolutionarily conserved domains of the p53 protein (Baker, et al. (1989), *Science*, 244:217, Hollstein, et al. (1991), *Science*, 253:49, and Soussi, et al. (1987), *Oncogene*, 1:71). Mutant p53 genes representing each of these hot-spot were transiently transfected into cells together with the PG₁₃-CAT reporter plasmid. The consistency of the result obtained with these mutant expression vectors was striking. All tumor-derived mutations examined had lost the ability to transactivate CAT, despite the wide range of positions (codons 143-273) in which these mutations were situated (Table 3, and Figure 16A). As might be expected for a cell line expressing low amounts of endogenous wild-type p53, there was often some innate transactivating ability associated with the HCT 116 cells themselves (Table 3; Fig. 13B, lane 1; Figure 16A, lane 1); interestingly, the levels of CAT observed with the mutants (Table 3 and Fig. 16A, lanes 4-7) were actually less than that observed with no exogenous p53 expression vector, suggesting that the mutant p53 products might be inhibiting the low amounts of expression mediated by the endogenous p53 (discussed below). The mutants studied included one which was typical of those found in the germline of Li-Fraumeni patients (248^{trp}) (Malkin, et al. (1990), *Science*, 250:1233; Strivastava, et al. (1990), *Nature*, 348:747) and three found commonly in a variety of human tumors (143^{val}, 175^{his}, 273^{his}) (Hollstein, et al. (1991), *Science*, 253:49). Immunoblots confirmed that mutant p53 proteins were expressed at levels comparable to those of wild-type p53 (Fig. 16B).

Western blots were performed as follows: 100 µg protein of each cell lysate was separated on a 10% polyacrylamide SDS gel, transferred onto a PVDF (Millipore, Bedford, MA) membrane, blocked with 5% nonfat milk, incubated with 1 µg/ml PAb1801 (Oncogene Sciences) then ¹²⁵I-labeled goat-anti-mouse Ab (NEN), and autoradiographed. The inability of p53 proteins having tumor-derived mutations to bind specifically to the p53 recognition sequences in this construct (Fig. 14, lanes 3-6) is thus consistently reflected as defects in transactivation.

Example 14

This example demonstrates that intact p53 transactivates in yeast.

We next sought to determine whether this activity of p53 was confined to mammalian cells. If the ability of p53 to bind to DNA sequences *in vivo* and activate the transcription of adjacent genes were an intrinsic feature of the protein, it was possible that this activity would be manifest in simpler eukaryotes. Indeed, the N-terminal acidic activation domain of p53 has been reported to function in *S. cerevisiae* when fused to the DNA-binding domain of GAL4 (Fields, et al. (1990), *Science*, 249:1046). We thus stably transfected yeast with the LacZ reporter gene placed downstream of PG multimers (PG_n-LacZ), as well as with a galactose-inducible p53 expression vector (Fig. 12). The addition of galactose to the medium resulted in p53 expression accompanied by a dramatic elevation in β-galactosidase expression (Table 4). When the MG multimer (non-p53 binding) was substituted for the PG multimer, no activation was observed (Table 4). Moreover, p53 mutants had no capacity

to transactivate in yeast cells (Table 4). Thus, the results in *S. cerevisiae* were analogous to those observed in human cells.

Table 4. Activation of Gene Expression in Yeast by p53

| p53 Expression Vector | Reporter | β-Gal Activity | |
|-----------------------------|-----------|----------------|--------|
| | | Exp. 1 | Exp. 2 |
| none | PG16-LacZ | 3 | 2 |
| Yp53 | PG16-LacZ | 13,000 | 8,000 |
| Yp53-143 | PG16-LacZ | 150 | 85 |
| Yp53-273 | PG16-LacZ | 5 | 2 |
| Yp53 | PG4-LacZ | 15,000 | 11,000 |
| Yp53 | PG1-LacZ | 2,600 | 3,000 |
| Yp53 | MG15-LacZ | 15 | 4 |

Wild-type or mutant p53 expression vectors and the β-galactosidase reporter plasmids were transfected into *S. cerevisiae* and clones obtained. p53 expression was induced with galactose, and β-galactosidase activity was measured in units of nanomoles per minute per milligram of protein. Two independent clones (Exp. 1 and Exp. 2) were tested. Less than 1 unit was seen in the absence of galactose induction. The residual activity of the Yp53-143 mutant may have been due to a slight wild-type activity observable with valine to alanine substitution mutants at the relatively low temperature (30°C) used for yeast growth.

Example 15

This example demonstrates the dominant-negative effect of p53 mutations on wild-type p53's ability to bind DNA and enhance transcription.

If the transcriptional activation of p53 were fundamental to its biological role, p53 mutants should be able to interfere with this activation, just as p53 mutants can interfere with the tumor-suppressor activity of wild-type p53 when both are expressed (Levine, et al. (1991), *Nature*, 351:453). To assess this possibility, we co-transfected the wild-type and mutant p53 genes with the PG₁₃-CAT reporter plasmid into HCT 116 cells (Figs. 17 and 18). When equal amounts of wild-type and mutant p53 expression vectors were used, the expression of CAT decreased by approximately 50% compared to that achieved by wild-type p53 alone. A three-fold ratio of mutant p53 to wild-type p53 produced an 84-95% reduction. When additional wild-type p53 was substituted for mutant p53 in the cotransfection experiment, the CAT expression increased rather than decreased, as expected (Fig. 18, "wt" lane). Thus, expression of the CAT reporter was dependent on the ratio of wild-type to mutant p53 in the cell.

The dominant-negative effect could be caused by a failure of the mutant/wild-type complexes to bind to DNA or to a failure to activate transcription once bound. To distinguish between these two possibilities, we co-translated wild-type p53 and the 175^{his} mutant of p53 in an experiment similar to that shown in Figure 14. The mutant p53 protein inhibited the ability of wild-type protein to bind DNA by over 90% when co-expressed at a 3:1 ratio.

SEQUENCE LISTING

SEQ ID NO: 1

1
 10
 20
 30
 40
 50
 60
 70
 80
 90
 100
 110
 120
 130
 140
 150
 160
 170
 180
 190
 200
 210
 220
 230
 240
 250
 260
 270
 280
 290
 300
 310
 320
 330
 340
 350
 360
 370
 380
 390
 400
 410
 420
 430
 440
 450
 460
 470
 480
 490
 500
 510
 520
 530
 540
 550
 560
 570
 580
 590
 600
 610
 620
 630
 640
 650
 660
 670
 680
 690
 700
 710
 720
 730
 740
 750
 760
 770
 780
 790
 800
 810
 820
 830
 840
 850
 860
 870
 880
 890
 900
 910
 920
 930
 940
 950
 960
 970
 980
 990
 1000
 1010
 1020
 1030
 1040
 1050
 1060
 1070
 1080
 1090
 1100
 1110
 1120
 1130
 1140
 1150
 1160
 1170
 1180
 1190
 1200
 1210
 1220
 1230
 1240
 1250
 1260
 1270
 1280
 1290
 1300
 1310
 1320
 1330
 1340
 1350
 1360
 1370
 1380
 1390
 1400
 1410
 1420
 1430
 1440
 1450
 1460
 1470
 1480
 1490
 1500
 1510
 1520
 1530
 1540
 1550
 1560
 1570
 1580
 1590
 1600
 1610
 1620
 1630
 1640
 1650
 1660
 1670
 1680
 1690
 1700
 1710
 1720
 1730
 1740
 1750
 1760
 1770
 1780
 1790
 1800
 1810
 1820
 1830
 1840
 1850
 1860
 1870
 1880
 1890
 1900
 1910
 1920
 1930
 1940
 1950
 1960
 1970
 1980
 1990
 2000
 2010
 2020
 2030
 2040
 2050
 2060
 2070
 2080
 2090
 2100
 2110
 2120
 2130
 2140
 2150
 2160
 2170
 2180
 2190
 2200
 2210
 2220
 2230
 2240
 2250
 2260
 2270
 2280
 2290
 2300
 2310
 2320
 2330
 2340
 2350
 2360
 2370
 2380
 2390
 2400
 2410
 2420
 2430
 2440
 2450
 2460
 2470
 2480
 2490
 2500
 2510
 2520
 2530
 2540
 2550
 2560
 2570
 2580
 2590
 2600
 2610
 2620
 2630
 2640
 2650
 2660
 2670
 2680
 2690
 2700
 2710
 2720
 2730
 2740
 2750
 2760
 2770
 2780
 2790
 2800
 2810
 2820
 2830
 2840
 2850
 2860
 2870
 2880
 2890
 2900
 2910
 2920
 2930
 2940
 2950
 2960
 2970
 2980
 2990
 3000
 3010
 3020
 3030
 3040
 3050
 3060
 3070
 3080
 3090
 3100
 3110
 3120
 3130
 3140
 3150
 3160
 3170
 3180
 3190
 3200
 3210
 3220
 3230
 3240
 3250
 3260
 3270
 3280
 3290
 3300
 3310
 3320
 3330
 3340
 3350
 3360
 3370
 3380
 3390
 3400
 3410
 3420
 3430
 3440
 3450
 3460
 3470
 3480
 3490
 3500
 3510
 3520
 3530
 3540
 3550
 3560
 3570
 3580
 3590
 3600
 3610
 3620
 3630
 3640
 3650
 3660
 3670
 3680
 3690
 3700
 3710
 3720
 3730
 3740
 3750
 3760
 3770
 3780
 3790
 3800
 3810
 3820
 3830
 3840
 3850
 3860
 3870
 3880
 3890
 3900
 3910
 3920
 3930
 3940
 3950
 3960
 3970
 3980
 3990
 4000
 4010
 4020
 4030
 4040
 4050
 4060
 4070
 4080
 4090
 4100
 4110
 4120
 4130
 4140
 4150
 4160
 4170
 4180
 4190
 4200
 4210
 4220
 4230
 4240
 4250
 4260
 4270
 4280
 4290
 4300
 4310
 4320
 4330
 4340
 4350
 4360
 4370
 4380
 4390
 4400
 4410
 4420
 4430
 4440
 4450
 4460
 4470
 4480
 4490
 4500
 4510
 4520
 4530
 4540
 4550
 4560
 4570
 4580
 4590
 4600
 4610
 4620
 4630
 4640
 4650
 4660
 4670
 4680
 4690
 4700
 4710
 4720
 4730
 4740
 4750
 4760
 4770
 4780
 4790
 4800
 4810
 4820
 4830
 4840
 4850
 4860
 4870
 4880
 4890
 4900
 4910
 4920
 4930
 4940
 4950
 4960
 4970
 4980
 4990
 5000
 5010
 5020
 5030
 5040
 5050
 5060
 5070
 5080
 5090
 5100
 5110
 5120
 5130
 5140
 5150
 5160
 5170
 5180
 5190
 5200
 5210
 5220
 5230
 5240
 5250
 5260
 5270
 5280
 5290
 5300
 5310
 5320
 5330
 5340
 5350
 5360
 5370
 5380
 5390
 5400
 5410
 5420
 5430
 5440
 5450
 5460
 5470
 5480
 5490
 5500
 5510
 5520
 5530
 5540
 5550
 5560
 5570
 5580
 5590
 5600
 5610
 5620
 5630
 5640
 5650
 5660
 5670
 5680
 5690
 5700
 5710
 5720
 5730
 5740
 5750
 5760
 5770
 5780
 5790
 5800
 5810
 5820
 5830
 5840
 5850
 5860
 5870
 5880
 5890
 5900
 5910
 5920
 5930
 5940
 5950
 5960
 5970
 5980
 5990
 6000
 6010
 6020
 6030
 6040
 6050
 6060
 6070
 6080
 6090
 6100
 6110
 6120
 6130
 6140
 6150
 6160
 6170
 6180
 6190
 6200
 6210
 6220
 6230
 6240
 6250
 6260
 6270
 6280
 6290
 6300
 6310
 6320
 6330
 6340
 6350
 6360
 6370
 6380
 6390
 6400
 6410
 6420
 6430
 6440
 6450
 6460
 6470
 6480
 6490
 6500
 6510
 6520
 6530
 6540
 6550
 6560
 6570
 6580
 6590
 6600
 6610
 6620
 6630
 6640
 6650
 6660
 6670
 6680
 6690
 6700
 6710
 6720
 6730
 6740
 6750
 6760
 6770
 6780
 6790
 6800
 6810
 6820
 6830
 6840
 6850
 6860
 6870
 6880
 6890
 6900
 6910
 6920
 6930
 6940
 6950
 6960
 6970
 6980
 6990
 7000
 7010
 7020
 7030
 7040
 7050
 7060
 7070
 7080
 7090
 7100
 7110
 7120
 7130
 7140
 7150
 7160
 7170
 7180
 7190
 7200
 7210
 7220
 7230
 7240
 7250
 7260
 7270
 7280
 7290
 7300
 7310
 7320
 7330
 7340
 7350
 7360
 7370
 7380
 7390
 7400
 7410
 7420
 7430
 7440
 7450
 7460
 7470
 7480
 7490
 7500
 7510
 7520
 7530
 7540
 7550
 7560
 7570
 7580
 7590
 7600
 7610
 7620
 7630
 7640
 7650
 7660
 7670
 7680
 7690
 7700
 7710
 7720
 7730
 7740
 7750
 7760
 7770
 7780
 7790
 7800
 7810
 7820
 7830
 7840
 7850
 7860
 7870
 7880
 7890
 7900
 7910
 7920
 7930
 7940
 7950
 7960
 7970
 7980
 7990
 8000
 8010
 8020
 8030
 8040
 8050
 8060
 8070
 8080
 8090
 8100
 8110
 8120
 8130
 8140
 8150
 8160
 8170
 8180
 8190
 8200
 8210
 8220
 8230
 8240
 8250
 8260
 8270
 8280
 8290
 8300
 8310
 8320
 8330
 8340
 8350
 8360
 8370
 8380
 8390
 8400
 8410
 8420
 8430
 8440
 8450
 8460
 8470
 8480
 8490
 8500
 8510
 8520
 8530
 8540
 8550
 8560
 8570
 8580
 8590
 8600
 8610
 8620
 8630
 8640
 8650
 8660
 8670
 8680
 8690
 8700
 8710
 8720
 8730
 8740
 8750
 8760
 8770
 8780
 8790
 8800
 8810
 8820
 8830
 8840
 8850
 8860
 8870
 8880
 8890
 8900
 8910
 8920
 8930
 8940
 8950
 8960
 8970
 8980
 8990
 9000
 9010
 9020
 9030
 9040
 9050
 9060
 9070
 9080
 9090
 9100
 9110
 9120
 9130
 9140
 9150
 9160
 9170
 9180
 9190
 9200
 9210
 9220
 9230
 9240
 9250
 9260
 9270
 9280
 9290
 9300
 9310
 9320
 9330
 9340
 9350
 9360
 9370
 9380
 9390
 9400
 9410
 9420
 9430
 9440
 9450
 9460
 9470
 9480
 9490
 9500
 9510
 9520
 9530
 9540
 9550
 9560
 9570
 9580
 9590
 9600
 9610
 9620
 9630
 9640
 9650
 9660
 9670
 9680
 9690
 9700
 9710
 9720
 9730
 9740
 9750
 9760
 9770
 9780
 9790
 9800
 9810
 9820
 9830
 9840
 9850
 9860
 9870
 9880
 9890
 9900
 9910
 9920
 9930
 9940
 9950
 9960
 9970
 9980
 9990
 10000
 10010
 10020
 10030
 10040
 10050
 10060
 10070
 10080
 10090
 10100
 10110
 10120
 10130
 10140
 10150
 10160
 10170
 10180
 10190
 10200
 10210
 10220
 10230
 10240
 10250
 10260
 10270
 10280
 10290
 10300
 10310
 10320
 10330
 10340
 10350
 10360
 10370
 10380
 10390
 10400
 10410
 10420
 10430
 10440
 10450
 10460
 10470
 10480
 10490
 10500
 10510
 10520
 10530
 10540
 10550
 10560
 10570
 10580
 10590
 10600
 10610
 10620
 10630
 10640
 10650
 10660
 10670
 10680
 10690
 10700
 10710
 10720
 10730
 10740
 10750
 10760
 10770
 10780
 10790
 10800
 10810
 10820
 10830
 10840
 10850
 10860
 10870
 10880
 10890
 10900
 10910
 10920
 10930
 10940
 10950
 10960
 10970
 10980
 10990
 11000
 11010
 11020
 11030
 11040
 11050
 11060
 11070
 11080
 11090
 11100
 11110
 11120
 11130
 11140
 11150
 11160
 11170
 11180
 11190
 11200
 11210
 11220
 11230
 11240
 11250
 11260
 11270
 11280
 11290
 11300
 11310
 11320
 11330
 11340
 11350
 11360
 11370
 11380
 11390
 11400
 11410
 11420
 11430
 11440
 11450
 11460
 11470
 11480
 11490
 11500
 11510
 11520
 11530
 11540
 11550
 11560
 11570
 11580
 11590
 11600
 11610
 11620
 11630
 11640
 11650
 11660
 11670
 11680
 11690
 11700
 11710
 11720
 11730
 11740
 11750
 11760
 11770
 11780
 11790
 11800
 11810
 11820
 11830
 11840
 11850
 11860
 11870
 11880
 11890
 11900
 11910
 11920
 11930
 11940
 11950
 11960
 11970
 11980
 11990
 12000
 12010
 12020
 12030
 12040
 12050
 12060
 12070
 12080
 12090
 12100
 12110
 12120
 12130
 12140
 12150
 12160
 12170
 12180
 12190
 12200
 12210
 12220
 12230
 12240
 12250
 12260
 12270
 12280
 12290
 12300
 12310
 12320
 12330
 12340
 12350
 12360
 12370
 12380
 12390
 12400
 12410
 12420
 12430
 12440
 12450
 12460
 12470
 12480
 12490
 12500
 12510
 12520
 12530
 12540
 12550
 12560
 12570
 12580
 12590
 12600
 12610
 12620
 12630
 12640
 12650
 12660
 12670
 12680
 12690
 12700
 12710
 12720
 12730
 12740
 12750
 12760
 12770
 12780
 12790
 12800
 12810
 12820
 12830
 12840
 12850
 12860
 12870
 12880
 12890
 12900
 12910
 12920
 12930
 12940
 12950
 12960
 12970
 12980
 12990
 13000
 13010
 13020
 13030
 13040
 13050
 13060
 13070
 13080
 13090
 13100
 13110
 13120
 13130
 13140
 13150
 13160
 13170
 13180
 13190
 13200
 13210
 13220
 13230
 13240
 13250
 13260
 13270
 13280
 13290
 13300
 13310
 13320
 13330
 13340

as shown in SEQ ID No:1.

4. The method of claim 1 wherein the p53-specific binding DNA fragment comprises more than one monomer of the sequence 5'-RRRCWWGYYY-3'.

5. The method of claim 1 wherein there are from 0 to 40 nucleotides between said monomers.

6. The method of claim 1 wherein the DNA fragment is labelled with a detectable moiety selected from the group consisting of:
a radioactive moiety, a colorimetric moiety, or a fluorescent moiety.

7. The method of claim 1 wherein the step of determining the amount of p53-specific binding DNA comprises: immunoprecipitating p53 protein with anti-p53 monoclonal antibodies.

8. A method of detecting the presence of a wild-type p53 protein in a cell, comprising the steps of:
providing a histological section from a human;
incubating the section with a detectably-labeled p53-specific binding DNA fragment to bind said DNA fragment to wild-type p53 present in the histological sample;
removing unbound DNA fragment from the histological section; and
determining the amount of DNA fragment which is bound to the histological sample.

9. The method of claim 8 wherein the p53-specific binding DNA segment comprises nucleotides 103 to 134 as shown in SEQ ID NO:1.

10. The method of claim 8 wherein the p53-specific binding DNA segment comprises nucleotides 104 to 123 as shown in SEQ ID NO:1.

11. The method of claim 8 wherein the p53-specific binding DNA fragment comprises more than one monomer of the sequence 5'-RRRCWWGYYY-3'.

12. The method of claim 11 wherein there are between 0 and 40 nucleotides between said monomers.

13. The method of claim 8 wherein the DNA fragment is labelled with a detectable moiety selected from the group consisting of:
a radioactive moiety, a colorimetric moiety, or a fluorescent moiety.

14. A method of providing the physiological effect of wild-type p53 protein to a cell, comprising the steps of:
providing to a cell a compound which is able to complex specifically with a p53-specific binding site.

15. The method of claim 14 wherein the compound comprises a single-stranded, linear or circular, oligonucleotide or oligonucleotide containing nucleotide analogs which can form a complex with a p53 specific DNA binding site.

16. The method of claim 14 wherein the compound comprises a polypeptide.

17. The method of claim 16 wherein the polypeptide comprises all or a part of human wild-type p53 protein.

18. The method of claim 15 wherein the oligonucleotide or oligonucleotide containing nucleotide analogs comprises the monomer sequence RRRCWWGYY or the complement thereof.

19. The method of claim 14 wherein the compound comprises at least a portion of the monomer sequence RRRCWWGYY as well as sequences adjacent to said monomer sequence in the human genome.

20. The method of claim 18 wherein the oligonucleotide or oligonucleotide containing nucleotide analogs comprises more than one monomer of said sequence.

21. The method of claim 18 wherein the oligonucleotide or oligonucleotide containing nucleotide analogs comprises between 0 and 40 nucleotides between said monomers.

22. A double-stranded DNA fragment which comprises a p53-specific DNA binding site, wherein the fragment

comprises more than one monomer of the sequence RRRCWWGYYY and wherein the fragment is covalently attached to an insoluble polymeric support.

23. A linear or circular single-stranded oligonucleotide or oligonucleotide containing nucleotide analogs which is able to complex specifically with a p53-specific binding site, said binding site comprising more than one monomer of the sequence RRRCWWGYYY.
24. The oligonucleotide or oligonucleotide containing nucleotide analogs of claim 23 which contains one or more switchback linkers which allow the oligonucleotide to complex with both strands of the p53-specific binding site.
25. The oligonucleotide or oligonucleotide containing nucleotide analogs of claim 23 which is selected from the group consisting of a methylphosphonate, an aminomethylphosphonate, a phosphorothioate, a phosphorodithioate, a substituted or unsubstituted phosphoramidate, an oligoribonucleotide, an oligodeoxyribonucleotide, an alpha-oligonucleotide and mixtures thereof.
26. The oligonucleotide or oligonucleotide containing nucleotide analogs of claim 23 which is terminated at the 3' or 5' end with a moiety which reduces susceptibility to oligonucleotide degradation or facilitates uptake by the cells.
27. The oligonucleotide or oligonucleotide containing nucleotide analogs of claim 26 wherein the moiety is selected from the group consisting of: a substituted or unsubstituted amino moiety, polyethylene glycol, polylysine, acridine, dodecanol, and cholesterol.
28. A method of identifying compounds which specifically bind to p53-specific DNA binding sequences, comprising the steps of:
 contacting a p53-specific-binding DNA fragment with a test compound to bind the test compound to the DNA fragment;
 determining the amount of test compound which is bound to the DNA fragment.
29. The method of claim 28 wherein soluble DNA fragments are incubated with the test compound and the p53-specific-binding DNA fragment immobilized on a solid support, said soluble DNA fragments not having the ability to specifically bind wild-type p53 protein.
30. A method of identifying compounds which specifically bind to p53-specific DNA binding sequences, comprising the steps of:
 contacting a p53-specific-binding DNA fragment immobilized on a solid support with both a test compound and wild-type p53 protein to bind the wild-type p53 protein to the DNA fragment;
 determining the amount of wild-type p53 protein which is bound to the DNA fragment, inhibition of binding of wild-type p53 protein by the test compound indicating binding of the test compound to the p53-specific DNA binding sequences.
31. A method of supplying wild-type p53 gene function to a cell which has lost said gene function by virtue of mutation in a p53 gene, comprising:
 introducing a wild-type p53 gene into a cell which has lost said gene function such that said gene is expressed in the cell.
32. The method of claim 31 wherein said wild-type p53 gene is expressed to a level higher than any mutant p53 gene present in the cell.
33. The method of claim 31 wherein the introduced wild-type p53 gene recombines with the endogenous mutant p53 gene present in the cell by a double recombination event to correct the p53 gene mutation.
34. A method of supplying a wild-type p53 gene function to a cell which has lost said gene function by virtue of a mutation in a p53 gene, comprising:
 introducing a portion of a wild-type p53 gene into a cell which has lost said gene function such that said portion is expressed in the cell, said portion encoding a part of the p53 protein which is required for non-neoplastic growth of said cell.
35. A method of pre-screening agents for use in cancer therapy, comprising:

measuring the amount of binding of a p53 protein encoded by a mutant gene found in cancer cells of a patient to a DNA molecule which conforms to the consensus binding site having more than one monomer of RRRCWWGYYY;

measuring the amount of binding of said p53 protein to said DNA molecule in the presence of a test substance; and

comparing the amount of binding of the p53 protein in the presence of said test substance to the amount of binding of the p53 protein in the absence of said test substance, a test substance which increases the amount of binding being a candidate for use in cancer therapy.

36. A method of pre-screening agents for use in cancer therapy, comprising:
 contacting a transfected cell with a test substance, said transfected cell containing a p53 protein which is encoded by a mutant gene found in cancer cells of a patient and a reporter gene construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to the p53 consensus binding site having more than one monomer of RRRCWWGYYY, wherein said sequence is upstream from and adjacent to said reporter gene; and

determining whether the amount of expression of said reporter gene is altered by the test substance, a test substance which alters the amount of expression of said reporter gene being a candidate for use in cancer therapy.

37. A method of pre-screening agents for use in cancer therapy, comprising:
 adding RNA polymerase and ribonucleotides to a transcription construct, said transcription construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to the p53 consensus binding site having at least two monomers of RRRCWWGYYY, said sequence being upstream from and adjacent to said reporter gene, said step of adding being effected in the presence and absence of a test substance; and

determining whether the amount of transcription of said reporter gene is altered by the presence of said test substance, a test substance which alters the amount of transcription of said reporter gene being a candidate for use in cancer therapy.

38. A DNA construct for use in screening potential chemotherapeutic agents, comprising:
 a reporter gene which encodes an assayable product;
 a sequence which conforms to the p53 consensus binding site having more than one monomer of RRRCWWGYYY upstream from and adjacent to said reporter gene, wherein said DNA construct is selected from the group consisting of a recombinant plasmid, a viral vector or an isolated molecule of DNA.

39. A method of diagnosing tumor-inducing or hyperplastic-inducing strains of human papilloma virus (HPV) comprising:
 contacting cells or cell extracts of patients suspected of being infected by HPV with a p53-specific binding DNA fragment;
 detecting the amount of wild-type p53 in said cells or cell extract which binds to said DNA fragment, absence of bound p53 indicating infection by strains of HPV which sequester p53.

40. A method of pre-screening agents for use in cancer therapy, comprising:
 contacting a transfected cell with a test substance, said transfected cell containing a wild-type p53 protein and a reporter gene construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to the p53 consensus binding site having more than one monomer of RRRCWWGYYY, wherein said sequence is upstream from and adjacent to said reporter gene; and
 determining whether the amount of expression of said reporter gene is altered by the test substance, a test substance which alters the amount of expression of said reporter gene being a candidate for use in cancer therapy.

41. A method of pre-screening oligonucleotides for use in cancer therapy, comprising:
 adding a p53 protein which is encoded by a mutant gene found in a cancer patient and a preparation of random oligonucleotides to a p53-specific-binding DNA fragment immobilized on a solid support;
 recovering the oligonucleotides which bound to the solid support.

FIG. 1A




FIG. 1B

| | | | | | | |
|------------|------|---|---|-------|---|---|
| Host cell: | HeLa | | | BSC40 | | |
| p53: | - | + | + | - | + | + |
| p53 Ab: | + | + | - | + | + | - |



FIG. 2A




FIG. 2B

| | | | | | |
|-----------------|----------|----------|----------|--------------------|----------|
| Protein source: | Vac | Vac | | Vac | Bac |
| p53: | - | wt | | 175 ^{his} | wt |
| | B | B | C | B | B |



28

[illegible]

FIG. 3B

← VECTOR
 1 10 20 30 40 50 60 70 80 90
 AAGCTTGATAATCATGGAGGTGAGTTTCCAGTGGTCTCATGATAGTGAAGTCTCCCATGATCTGATGGTTTATTAAGGGCA
 TTCGAACCTATTAGTACCTCCACTCAAAAGGTCAAGAGTACTAGCACTGATTCAGAGGTACTAGACTACCAAAATTTTCCCGT
 100 110 120 130 140 150 160 170 180
 GTCCCTTCTACAGATGCTCTCTTGGCTTGGCTACCAATGTAGACATGCTGTGCTCTCTTCTGCTTCTGCTGAGACCTTCCCA
 CAGGAAGATGTGTACGAGAGCAACCAAGTACATTTCTGTACGGACACGAGGAGAAACGGAAGACGGTACTTAACTCTGGAAGGGT
 → VECTOR
 190 200 210 220 230
 GCCATGTGGAACTGTGAGTATCGAATTCCTGCAGCCCGGGGATCCACTAGTTCTAGA
 CCGTACACCTTGACACTCATAGCTTAAGGACGTGGGGCCCCCTAGGTGATCAAGATCT

FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7A




FIG. 7B





FIG. 8A

FIG. 8B





FIG. 9



BNSDOCID: <EP__0518650A2J_>

| CLONE | SIZE 5'- (bp) | nnnnnnnnnnnnnnnnnn | R R R C W W G Y Y Y | nnnnnnnnnnnnnnnnnn | R R R C W W G Y Y Y | nnnnnnnnnnnnnnnnnn | 3'- (bp) |
|------------|------------------|--------------------|-------------------------|--------------------|-----------------------|--------------------|-------------|
| 1. S57 | 295 144 | cgacctgtcacaccg | GGG C c T G T C a | | c A G C A T G a C C T | acctgtcacaccggg | 194 |
| 2. N22 | 357 178 | attttcaccatgctt | c t G C A T G T C T | | A G G C A A G T C a | ccctctccactggcc | 227 |
| 3. 11A2 | 387 317 | ccccatcctccactg | A A C A a T G C C C | | A G A C T T G T C T | ctccggccctgaatga | 367 |
| 4. W211 | 249 119 | tttgtcctaccatcc | A G G C A T G C C C T | | T T G T C C T | cactcgttatctct | 164 |
| 5. W7B2 | 139 41 | tatctgtgcagctgt | G G G C A T G T T T | t | A G G C A A G C T T | ccgtgtgctagttccc | 91 |
| 6. 3H | 126 50 | aactagatcccttttc | A G G C A T G T T a | | t A A C A A G T C a | gtacaagtttatttt | 99 |
| 7. 8A | 483 445 | gctgggtgcacaagag | t G A C A T G T T C C | | c G A C g T G T T T | tgctc | 483 |
| 8. 532 | 335 229 | catcatgccaccctgc | A G G C A T G T T C C | tggaat | G G G C T G T T C T | tgctcttggttggttt | 282 |
| 9. 64A2 | 349 120 | caaacagggtgtct | t G A C T T G C C C T | atccctgggagggt | t G A C A T G T T C | ctccccctccccctc | 181 |
| 10. W7A1 | 264 124 | gccaaacataaaccac | c A G C T G C C C a | | A G G C A T G C a g | taccacgctcagccc | 173 |
| 11. S61 | 202 1 | actgttgatgatgaa | c A C T T G T C T T | attctgtgttgat | G G A C A T G T T C | ccgtttttggctatt | 49 |
| 12. 11B3 | 248 201 | gcagtgtggtggagg | A G A C A A G C C T a | a | G G G C A g T C C | tgggggggtggggg | 248 |
| 13. N42 | 248 49 | gttcataacctgtcc | A A A C A A G C C C C | a | G G A t g T G C C C | agggcaggctgggac | 99 |
| 14. S201 | 326 164 | ctttaattcagttgt | A c A C A T T G T C T | | A t A C c T G C C T | acacctgtcttggtt | 214 |
| 15. S15B3 | 248 83 | ctcagttctcagctg | A A A C A T G a C T T | gttcattata | t G A C A T G T T C | aattacaattcgatt | 143 |
| 16. S592I | 254 39 | tgccctcagcaccttc | G G A C T T G C C C C | | t G G C c A G C C C | tggggctcactgcctgc | 88 |
| 17. S592II | 254 130 | gcctttgtttgtgccc | A G G t T c T G C C C | | G G G C T T G T T C | cttttcttttcagcat | 179 |
| 18. 2HB | 470 42 | gtattctcttttctct | t G A C T T G C C C C | | A G A C A T G T T T | gggaatgtctttgtgc | 91 |
| 19. 9H | 467 108 | tgaaagcaggtagat | A A G C A T T G C C C T | | t G A C T T G T T C | tttcatctctctctga | 157 |
| 20. CBE10d | 425 89 | | t G c c T T G C C C T | | G G A C T T G C C T | ggccttgcctttttct | 138 |

FIG. 10B

COMBINED NUCLEOTIDE USAGE (%) WITHIN THE TWO MONOMERS OF THE CONSENSUS BINDING SITE:

| | 5'- | R | R | R | C | W | W | G | Y | Y | Y | 3'- |
|---|-----------|-----------|-----------|-----------|-----------|-----------|------------|-----------|-----------|-----------|---|-----|
| A | <u>40</u> | <u>20</u> | <u>55</u> | 0 | <u>53</u> | <u>15</u> | 0 | 0 | 0 | 12 | A | |
| C | 13 | 3 | 3 | <u>93</u> | 8 | 0 | 0 | <u>50</u> | <u>68</u> | <u>35</u> | C | |
| G | <u>23</u> | <u>70</u> | <u>40</u> | 0 | 8 | 3 | <u>100</u> | 0 | 0 | 3 | G | |
| T | 23 | 5 | 0 | 5 | <u>30</u> | <u>82</u> | 0 | <u>50</u> | <u>30</u> | <u>48</u> | T | |

SYNTHETIC
OLIGONUCLEOTIDES:
NO. p53 BINDING

| | | |
|-----|---|-------------|
| 1. | - | AGG aATtCCT |
| 2. | - | AGG aATtCCT |
| 3. | - | AGGCATGTCT |
| 4. | + | AGGCATGTCT |
| 5. | - | AGGCAAGgCa |
| 6. | + | AGGCATGTCT |
| 7. | + | AGGCATGTCT |
| 8. | + | AGCATGCTT |
| 9. | - | AGGCATGTCT |
| 10. | - | AGGCATGTCT |

tgcaggaattcgat
 tgcaggaattcgat
 tgcaggaattcgat
 tgcaggaattcgat
 tgcaggaattcgat

AGGaATtCCT

AGGCATGCCT
 AGGCAAGgCa
 AGGCATGTCT
 AGCATGCTT
 AGGCATGTCT

atcaagcittatcgat
 atcaagcittatcgat
 atcaagcittatcgat
 atcaagcittatcgat
 atcaagcittatcgat

FIG. IIA





FIG. IIB




**FIG. 12A**


FIG. 12B

FIG. 13A




FIG. 13B




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 17

| | | | | | |
|------------------------|----|----|-----|-----|------|
| p53-wt (ug): | 0 | 85 | 85 | .85 | .85 |
| p53-175 (ug): | 0 | 0 | 0 | .85 | 2.55 |
| PG ₁₃ -CAT: | + | - | + | + | + |
| Activity: | 12 | 0 | 100 | 44 | 11 |




FIG. 18




FIG. 19

